document incorporate referencefontb center table width aligncenter cellspace cellpadde border widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizepartsnbspi iii fontdiv tdfont sizenbspfonttd alignleft valigntop font sizeportion registrant annual report shareholder fiscal year annual report fonttd alignleft valigntopdiv stylemarginleft textindent font sizepart iii fontdiv tdfont sizenbspfonttd alignleft valigntop font sizeportion registrant proxy statement annual meeting proxy statement fonttd table center alignleft size width alignleft colorblack noshade div alignleft size width alignleft colorblack noshade div pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp aligncenter bfont sizepart ifontb center table width aligncenter cellspace cellpadde border widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd colspan aligncenter nowrapbfont sizeitemfontbtd tdtd tdtd tdtd colspan aligncenter nowrapbfont sizefontbtd colspan aligncenter nowraphr size noshadetd tdtd tdtd tdtd colspan aligncenter nowraphr size noshadetd valignbottom bgcoloreeeeee alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizebusiness fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop nbspnbspfont sizegeneral fonttdtdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop nbspnbspfont sizesegment business fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop nbspnbspfont sizeconsumer fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop nbspnbspfont sizepharmaceutical fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop nbspnbspfont sizemedical device diagnostic fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop nbspnbspfont sizegeographic area fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttdtd alignleft valigntop nbspnbspfont sizeraw material fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop nbspnbspfont sizepatent trademark fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop nbspnbspfont sizeseasonality fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop nbspnbspfont sizecompetition fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop nbspnbspfont sizeresearch fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop nbspnbspfont sizeenvironment fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttdtd alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop nbspnbspfont sizeregulation fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop nbspnbspfont sizeavailable information fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizeafonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizerisk factor fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizebfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizeunresolve staff comment fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizepropertie fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizelegal proceeding fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd trtr alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizesubmission matter vote security holder fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop nbspnbspfont sizeexecutive officer registrant fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd colspan aligncenter valigntop bfont sizepartnbspiifontbtd valignbottom bgcoloreeeeee alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizemarket registrant common equity relate stockholder matter issuer purchase equity security fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizeselecte financial datum fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizemanagement discussion analysis financial condition result operation fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd trtr alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizeafonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizequantitative qualitative disclosure market risk fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizefinancial statement supplementary datum fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizechange disagreement accountant account financial disclosure fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizeafonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizecontrol procedure fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizebfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizeother information fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee colspan aligncenter valigntop bfont sizepartnbspiiifontbtd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttdtdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizedirector executive officer registrant fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizeexecutive compensation fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizesecurity ownership certain beneficial owner management relate stockholder matter fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizecertain relationship relate transaction fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizeprincipal accounting fee service fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee colspan aligncenter valigntop bfont sizepartnbspivfontbtd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizeexhibit financial statement schedulesfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizesignature fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizereport independent register public accounting firm financial statement schedule fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizeexhibit index fonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd table center pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp aligncenter bfont sizepart ifontb alignleft bfont sizeitem nbspnbspbusinessfontb alignleft bfont sizegeneralfontb alignleftnbspnbspnbspnbspnbsp font sizejohnsonnbsp johnson subsidiary approximately employee worldwide engage manufacture sale broad range product health care field johnson johnson operate company conduct business virtually country world johnsonnbsp johnsons primary focus product relate human health wellbee johnsonnbsp johnson incorporate state new jersey font alignleftnbspnbspnbspnbspnbsp font sizethe companys structure base principle decentralize management executive committeeof johnsonnbsp johnson principal management group responsible operation allocation resource company committee oversee coordinate activitie consumer pharmaceutical medical device diagnostic business segment subsidiary business segment exception manage citizen country locate font alignleft bfont sizesegment businessfontb alignleftnbspnbspnbspnbspnbsp font sizejohnsonnbsp johnson worldwide business divide segment consumer pharmaceutical medical device diagnostic additional information require item incorporate reference narrative tabular graphic description segment operate result management discussion analysis result operation financial condition pagesnbsp notenbsp segment business geographic area note consolidated financial statement nbsp annual report file exhibitnbsp report formnbspk font alignleft bfont sizeconsumerfontb alignleftnbspnbspnbspnbspnbsp font sizethe consumer segment manufacture market broad range product baby childnbspcare skin care oral wound care womens health care field nutritional overthecounter pharmaceutical product major brand include aveenosup stylefontsize verticalalign texttopsup skin care product bandaidsup stylefontsize verticalalign texttopsup brand adhesive bandage carefreesup stylefontsize verticalalign texttopsup pantiliners cleannbsp clearsup stylefontsize verticalalign texttopsup teen skin care product johnsonssup stylefontsize verticalalign texttopsup baby adult line product motrinsup stylefontsize verticalalign texttopsup ibuprofen product pepcidsup stylefontsize verticalalign texttopsup acid controller johnsonnbsp johnsonnbsp merck consumer pharmaceutical neutrogenasup stylefontsize verticalalign texttopsup skin hair care product rocsup stylefontsize verticalalign texttopsup skin care product splendasup stylefontsize verticalalign texttopsup calorie sweetener stayfreesup stylefontsize verticalalign texttopsup sanitary protection product broad family tylenolsup stylefontsize verticalalign texttopsup acetaminophen product product available prescription market principally general public sell wholesaler directly independent chain retail outlet world font alignleft bfont sizepharmaceuticalfontb alignleftnbspnbspnbspnbspnbsp font sizethe pharmaceutical segment include product follow therapeutic area antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology product distribute directly retailer wholesaler health care professional prescription use general public key product pharmaceutical segment include risperdalsup stylefontsize verticalalign texttopsup risperidone risperdalsup stylefontsize verticalalign texttopsupconstasup stylefontsize verticalalign texttopsup risperidone longacte injection treatment symptom schizophrenia procritsup stylefontsize verticalalign texttopsup epoetin alfa sell outside eprexsup stylefontsize verticalalign texttopsup biotechnologyderive product stimulate red blood cell production remicadesup stylefontsize verticalalign texttopsup infliximab monoclonal antibody therapy indicate treat symptom crohns disease rheumatoid arthritis ankylose spondylitis psoriatic arthritis ulcerative colitis topamaxsup stylefontsize verticalalign texttopsup topiramate antiepileptic migraine prevention treatment duragesicsup stylefontsize verticalalign texttopsup fentanyl transdermal system sell outside durogesicsup stylefontsize verticalalign texttopsup treatment chronic pain offer novel delivery system levaquinsup stylefontsize verticalalign texttopsup levofloxacin floxinsup stylefontsize verticalalign texttopsup ofloxacin antiinfective field ortho evrasup stylefontsize verticalalign texttopsup norelgestrominethinyl estradiol transdermal system contraceptive patch approve food drug administration fda orthonbsptricyclensup stylefontsize verticalalign texttopsupnbsplo norgestimateethinyl estradiol low dose oral contraceptive font aligncenter pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp div alignleft font sizedoxilsup stylefontsize verticalalign texttopsup doxorubicin hci liposome injection cancer treatment ditropansup stylefontsize verticalalign texttopsup oxybutynin chloride treatment overactive bladder razadynesuptmsup galantamine hbr patient mild moderate alzheimer disease natrecorsup stylefontsize verticalalign texttopsup nesiritide novel agent approve congestive heart failure velcadesup stylefontsize verticalalign texttopsup bortezomib oncology treatment concertasup stylefontsize verticalalign texttopsup methylphenidate hcl product treatment attention deficit hyperactivity disorder font div alignleft bfont sizemedical device diagnosticsfontb alignleftnbspnbspnbspnbspnbsp font sizethe medical device diagnostic segment include broad range product distribute wholesaler hospital retailer principally professional field physician nurse therapist hospital diagnostic laboratory clinic product include cordis circulatory disease management product depuy orthopaedic joint reconstruction spinal care product ethicon wound care women health product ethicon endosurgerys minimally invasive surgical product lifescan blood glucose monitoring product orthoclinical diagnostic professional diagnostic product vision care disposable contact lense distribution health care professional market directly surgical supply dealer font alignleft bfont sizegeographic areasfontb alignleftnbspnbspnbspnbspnbspfont sizethe international business johnson johnson conduct subsidiary locate country outside united states sell product virtually country world product sell international business include describe businessnbsp consumer nbsppharmaceutical nbspmedical device diagnostic principal market product method distribution international business vary country culture product sell international business include develop united states develop subsidiary abroad font alignleftnbspnbspnbspnbspnbsp font sizeinvestment activity country outside united states subject high risk comparable activity investment commercial climate influence restrictive economic policy political uncertainty font alignleft bfont sizeraw materialsfontb alignleftnbspnbspnbspnbspnbsp font sizeraw material essential johnson johnsons operate company business generally readily available multiple source font alignleft bfont sizepatent trademarksfontb alignleftnbspnbspnbspnbspnbsp font sizejohnson johnson practice obtain patent protection product process possible johnson johnson own license number patent relate product manufacturing process aggregate believe material importance operation business sale company large product risperdalsup stylefontsize verticalalign texttopsup procritsup stylefontsize verticalalign texttopsupeprexsup stylefontsize verticalalign texttopsup account approximately johnson johnsons total revenue respectively fiscal accordingly patent relate product believe material relation johnson johnson font alignleftnbspnbspnbspnbspnbsp font sizedure duragesicsup stylefontsize verticalalign texttopsup fentanyl transdermal system united states certain international market eprexsup stylefontsize verticalalign texttopsup epoetin alfa international market lose lose basic patent protection subject generic competition duragesicsup stylefontsize verticalalign texttopsup sale decline nbspbillion compare negative impact generic competition primarily unite state eprexsup stylefontsize verticalalign texttopsup generic competition limit near term lack approve generic compound combine sale duragesicsup stylefontsize verticalalign texttopsup eprexsup stylefontsize verticalalign texttopsup account approximately johnsonnbsp johnson worldwide sale material patent schedule expire year related risperdalsup stylefontsize verticalalign texttopsup schedule expire united states december possibility pediatric extension fontp aligncenterfont size font pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp alignleftnbspnbspnbspnbspnbsp font sizejohnson johnson practice sell product trademark obtain protection trademark available mean johnson johnson trademark protect registration united states country product market johnson johnson consider trademark aggregate material importance operation business font alignleft bfont sizeseasonalityfontb alignleftnbspnbspnbspnbspnbsp font sizeworldwide sale reflect significant degree seasonality spend heavy fourth quarter year quarter reflect increase spending decision principally advertise research grant font alignleft bfont sizecompetitionfontb alignleftnbspnbspnbspnbspnbsp font sizein product line johnson johnson company compete company large small locate world competition strong product line regard number size compete company involve competition research involve development improvement new exist product process particularly significant development new improve product important johnson johnson success area business competitive environment require substantial investment continue research multiple sale force addition development maintenance customer acceptance product johnson johnsons consumer business involve significant expenditure advertising promotion font alignleft bfont sizeresearchfontb alignleftnbspnbspnbspnbspnbsp font sizeresearch activity important segment johnson johnsons business major research facility locate united states australia belgium brazil canada china france germany japan netherlands united kingdom cost worldwide companysponsore research activity relate development new product improvement exist product technical support product compliance governmental regulation protection consumer patient exclude inprocess research development charge amount nbspmillion nbspmillion nbspmillion fiscal year respectively cost charge directly income year incur font alignleft bfont sizeenvironmentfontb alignleftnbspnbspnbspnbspnbsp font sizedure past year johnson johnson companies subject variety federal state local environmental protection measure johnson johnson believe operation comply material respect applicable environmental law regulation johnson johnson compliance requirement expect material effect capital expenditure cash flow earning competitive position fontp alignleft bfont sizeregulationfontb alignleftnbspnbspnbspnbspnbsp font sizemost johnson johnsons business subject vary degree governmental regulation country operation conduct general trend regulation increase stringency united states drug device diagnostic cosmetic industry long subject regulation federal state agency primarily product safety efficacy manufacturing advertising labeling exercise broad regulatory power fda continue result increase amount test documentation require fda clearance new drug device correspond increase expense product introduction similar trend evident major market outside united states font alignleftnbspnbspnbspnbspnbsp font sizethe cost human health care continue subject study investigation regulation governmental agency legislative body world united states attention focus drug price profit program encourage doctor write prescription particular drug recommend use purchase particular medical device payer potent font aligncenterfont size font pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp div alignleft font sizeforce market place increase attention pay drug medical device price appropriate drug medical device utilization quality cost health care uncertainty united states impact medicare prescription drug improvement modernization act enact font div alignleftnbspnbspnbspnbspnbsp font sizethe regulatory agency purview johnson johnson company operate administrative power subject company action product withdrawal recall seizure product civil criminal sanction case johnson johnson operating company deem advisable initiate product recall font alignleftnbspnbspnbspnbspnbsp font sizein addition business practice health care industry come increase scrutiny particularly united states government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty font divnbspdiv table width border cellpadding cellspace widthtd widthtd valigntop tdtd bfont sizeavailable informationfontbtd tablep alignleftnbspnbspnbspnbspnbsp font sizecopies johnson johnsons quarterly report formnbspq annual report formnbspk current report formnbspk amendment forego provide charge shareholder submit write request secretary principal executive office company call company securities exchange commission sec filing available company web site iwwwinvestorjnjcomgovernancei soon reasonably practicable electronically file furnish sec sec filing available sec web site iwwwsecgovi addition charter audit committee compensation benefit committee nominate corporate governance committee board director company principle corporate governance policy business conduct employee code business conduct ethic member board director executive officer available iwwwinvestorjnjcomgovernancei web site address provide charge shareholder submit write request provide font alignleft bfont sizeitem anbspnbspnbspnbspnbsprisk factorsfontb alignleftnbspnbspnbspnbspnbsp font sizenot applicable font alignleft bfont sizeitem bnbspnbspnbspnbspnbspunresolve staff commentsfontb alignleftnbspnbspnbspnbspnbsp font sizenot applicable font alignleft bfont sizeitem nbspnbspnbspnbspnbsppropertiesfontb alignleftnbspnbspnbspnbspnbsp font sizejohnson johnson worldwide subsidiary operate manufacturing facility occupy approximately nbspmillion square foot floor space font alignleftnbspnbspnbspnbspnbsp font sizethe manufacturing facility industry segment johnson johnsons business approximately follow font center table width aligncenter cellspace cellpadde border widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd colspantd tdtd colspan aligncenter nowrapbfont sizesquare feetfontbtd colspan aligncenter nowrapbfont sizesegmentfontbtd tdtd colspan aligncenter nowrapbfont sizein thousandsfontbtdtr colspan aligncenter nowraphr size noshadetd tdtd colspan aligncenter nowraphr size noshadetd valignbottom bgcoloreeeeee colspan alignleft valigntop div stylemarginleft textindent font sizeconsumer fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd colspan alignleft valigntop div stylemarginleft textindent font sizepharmaceutical fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee colspan alignleft valigntop div stylemarginleft textindent font sizemedical device diagnostic fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd colspanfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeworldwide total fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd colspanfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd table center alignleftnbspnbspnbspnbspnbsp font sizewithin united states nbspfacilitie consumer segment pharmaceutical segmentand medical device diagnostic segment johnsonnbsp johnson manufacture operation outside united states conduct facility serve segment business font aligncenterfont size font pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp alignleftnbspnbspnbspnbspnbsp font sizethe location manufacture facility major geographic area world follow font center table width aligncenter cellspace cellpadde border widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd colspantd tdtd colspan aligncenter nowrapbfont sizenumberfontbtd tdtd colspantd colspantd tdtd colspan aligncenter nowrapbfont sizeoffontbtd tdtd colspan aligncenter nowrapbfont sizesquare feetfontbtd colspan aligncenter nowrapbfont sizegeographic areafontbtd tdtd colspan aligncenter nowrapbfont sizefacilitiesfontbtd tdtd colspan aligncenter nowrapbfont sizein thousandsfontbtd colspan aligncenter nowraphr size noshadetd tdtd colspan aligncenter nowraphr size noshadetd tdtd colspan aligncenter nowraphr size noshadetd valignbottom bgcoloreeeeee colspan alignleft valigntop div stylemarginleft textindent font sizeunited state fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd trtr colspan alignleft valigntop div stylemarginleft textindent font sizeeurope fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee colspan alignleft valigntop div stylemarginleft textindent font sizewestern hemisphere exclude usa fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd colspan alignleft valigntop div stylemarginleft textindent font sizeafrica asia pacific fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd colspanfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeworldwide total fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd colspanfont sizenbspfonttdtdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd table center alignleftnbspnbspnbspnbspnbsp font sizein addition manufacture facility discuss johnson johnson maintain numerous office warehouse facility world research facility discuss item business research font alignleftnbspnbspnbspnbspnbsp font sizejohnson johnson generally seek manufacture facility principally location abroad lease office warehouse facility lease font alignleftnbspnbspnbspnbspnbsp font sizejohnson johnson property maintain good operating condition repair utilize font alignleftnbspnbspnbspnbspnbsp font sizefor information lease obligation notenbsp rental expense lease commitment note consolidated financial statement nbsp annual report file exhibitnbsp report formnbspk segment information addition property plant equipment contain notenbsp segment business geographic area note consolidated financial statement nbsp annual report file exhibitnbsp report formnbspk font alignleft bfont sizeitem nbspnbspnbspnbspnbsplegal proceedingsfontb alignleftnbspnbspnbspnbspnbsp font sizethe information set forth note legal proceeding note consolidated financial statement pagesnbsp annual report incorporate reference file exhibitnbsp report formnbspk font alignleftnbspnbspnbspnbspnbsp font sizethe company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund comparable state law primary relief seek cost past future remediation feasible predict determine outcome proceeding opinion company proceeding material adverse effect result operation cash flow financial position company font alignleft bfont sizeitem nbspnbspsubmission matter vote security holdersfontb alignleftnbspnbspnbspnbspnbsp font sizenot applicable fontp alignleft bfont sizeexecutive officer registrantfontb alignleftnbspnbspnbspnbspnbsp font sizeliste executive officer johnson johnson marchnbsp indicate employee company affiliate hold position indicate past year family relationship executive officer arrangement understand executive officer person pursuant executive officer select annual meeting board director executive officer elect board hold office year respective successor elect qualified early resignation removal font aligncenterfont size font pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp alignleftnbspnbspnbspnbspnbsp font sizeinformation regard director company include follow executive officer director incorporate reference pagesnbsp johnson johnsons proxy statement date marchnbsp font center table width aligncenter cellspace cellpadde border widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd aligncenter nowrapbfont sizenamefontbtd tdtd colspan aligncenter nowrapbfont sizeagefontbtd tdtd aligncenter nowrapbfont sizepositionfontbtd aligncenter nowraphr size noshadetd tdtd colspan aligncenter nowraphr size noshadetd tdtd aligncenter nowraphr size noshadetd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizerobert darretta fontdiv tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizevice chairman board directors member executive committee chief financial officer fontdiv trtr alignleft valigntop div stylemarginleft textindent font sizerussell deyo fontdiv tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizemember executive committee vice president general counsel chief compliance officera fontdiv valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizemichael dormer fontdiv tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizemember executive committee worldwide chairman medical devicesb fontdiv alignleft valigntop div stylemarginleft textindent font sizekaye fostercheek fontdiv tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizemember executive committee vice president human resourcesc fontdiv valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizecolleen goggin fontdiv tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizemember executive committee worldwide chairman consumer personal care groupd fontdiv alignleft valigntop div stylemarginleft textindent font sizeper peterson phdnbspfontdiv tdtdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizemember executive committee chairman research development pharmaceutical groupe fontdiv valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizechristine poon fontdiv tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizevice chairman board directors member executive committee worldwide chairman medicine nutritional fontdiv alignleft valigntop div stylemarginleft textindent font sizejoseph scodari fontdiv tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizemember executive committee worldwide chairman pharmaceutical groupf fontdiv valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizenicholas valeriani fontdiv tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizemember executive committee worldwide chairman cardiovascular device diagnosticsg fontdiv alignleft valigntop div stylemarginleft textindent font sizewilliam weldon fontdiv tdfont sizenbspfonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttdtdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizechairman board directors chairman executive committee chief executive officer fontdiv table center div alignleft size width alignleft colorblack noshade div table width border cellpadding cellspace widthtd widthtd valigntop tdfont sizeafonttd alignleft font sizemr deyo join company associate general counsel member executive committee vice president administration vice president general counsel chief compliance officer april fonttd tdnbsptd valigntop tdfont sizebfonttd alignleft font sizemrnbspmnbspj dormer join company company group chairman worldwide franchise chairman depuy codman company acquire depuy inc time acquisition chief operating officer depuy inc mrnbspdormer member executive committee franchise group chairman medical device aprilnbsp mrnbspdormer name worldwide chairman medical device fonttd tdnbsptd valigntop tdfont sizecfonttd alignleft font sizemsnbspknbspi fostercheek join company vice president human resources johnson johnson consumer product company march name vice president human resource consumer personal care group name member human resource leadership team consumer personal care group operating committee fostercheek member executive committee vice president human resource company january prior join company msnbspfostercheek serve human resource management position pfizer inc nbspyear recently support pharmaceutical business japan asia africa middle east latin america fonttd table table width border cellpadding cellspace trtd widthtd widthtd valigntop tdfont sizednbspfonttd alignleft font sizemsnbspc goggin join company hold position president personal product company name president johnson johnson consumer product company company group chairman north america johnson johnson consumer product msnbspgoggin member executive committee worldwide chairman consumer personal care group fonttd table table width border cellpadding cellspace widthtd widthtd valigntop tdfont sizeefonttd alignleft font sizedrnbsppnbspa peterson join company vice president drug discovery rwnbspjohnson pharmaceutical research institute name group vice president pharmaceutical research institute april president november drnbsppeterson name chairman research development pharmaceutical group drnbsppeterson member executive committee fonttd table aligncenterfont size font pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp table width border cellpadding cellspace widthtd widthtd valigntop tdfont sizeffonttd alignleft font sizemrnbspjnbspc scodari join company president centocor company acquire centocor time acquisition president chief operating officer centocor member centocors board director december march name company group chairman north american pharmaceutical business member pharmaceutical group operating committee march mrnbspscodari name company group chairman biopharmaceutical business mrnbspscodari name worldwide chairman pharmaceutical group member executive committee marchnbsp fonttd table table width border cellpadde cellspacingtr widthtd widthtd valigntop tdfont sizegfonttd alignleft font sizemr nnbspj valeriani join company hold position president ethicon endosurgery inc january name company group chairman ethicon endosurgery additional responsibility johnsonnbsp johnson medical product medical device diagnostic business canada worldwide franchise chairman depuy franchise mrnbspvaleriani member executive committee vice president human resource september february assume additional responsibility worldwide chairman diagnostic january mrnbspvaleriani appoint worldwide chairman cardiovascular device diagnostic relinquish human resource responsibility fonttd table alignleft aligncenter bfont sizepart iifontb divnbspdiv table width border cellpadding cellspace widthtd widthtd valigntop tdbfont sizeitem fontbtd bfont sizemarket registrant common equity relate stockholder matter issuer purchase equity securitiesfontbtd table alignleftnbspnbspnbspnbspnbsp font sizea februarynbsp record holder common stock company information call item incorporate reference material caption management discussion analysis result operation financial conditionnbsp dividend nbsp common stock market price nbsp notenbsp note consolidated financial statement nbsp annual report file exhibitnbsp report formnbspk font alignleft bfont sizeissuer purchase equity securitiesfontb alignleftnbspnbspnbspnbspnbsp font sizethe follow table provide information respect common stock share purchase company fiscal fourth quarter stock purchase systematic plan meet company compensation program font center table width aligncenter cellspace cellpadde border trtd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd tdtd tdtd colspan aligncenter nowrapbfont sizetotal number sharesfontbtd tdtd colspan aligncenter nowrapbfont sizeaverage price paidfontbtd alignleft nowrapbfont sizefiscal monthfontbtd tdtd colspan aligncenter nowrapbfont sizepurchasedfontbtd tdtd colspan aligncenter nowrapbfont sizeper sharefontbtd aligncenter nowraphr size noshadetd tdtd colspan aligncenter nowraphr size noshadetd tdtd colspan aligncenter nowraphr size noshadetd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizeoctobernbsp octobernbsp fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizefonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeoctobernbsp novembernbsp fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizefonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizenovembernbsp januarynbsp fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizefonttdtd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd table center alignleft bfont sizeitem nbspnbspnbspnbspnbspselecte financial datafontb alignleftnbspnbspnbspnbspnbsp font sizethe information call item incorporate reference material caption summary operation statistical datum nbsp annual report file exhibitnbsp report formnbspk font divnbspdiv table width border cellpadding cellspace widthtd widthtd valigntop tdbfont sizeitem fontbtd bfont sizemanagement discussion analysis financial condition result operationsfontbtd table alignleftnbspnbspnbspnbspnbsp font sizethe information call item incorporate reference narrative tabular graphic material include management discussion analysis result operation financial condition pagesnbsp annual report file exhibitnbsp report formnbspk font aligncenterfont size font pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp alignleft bfont sizeitemnbspanbspnbspnbspnbspnbspquantitative qualitative disclosure market riskfontb alignleftnbspnbspnbspnbspnbsp font sizethe information call item incorporate reference narrative graphic material caption management discussion analysis result operation financial conditionnbsp liquidity capital resource pagesnbsp annual report file exhibitnbsp report formnbspk font alignleft bfont sizeitem nbspnbspnbspnbspnbspfinancial statement supplementary datafontb alignleftnbspnbspnbspnbspnbsp font sizethe information call item incorporate reference audit consolidated financial statement note thereto material caption report independent register public accounting firm pagesnbsp annual report file exhibitnbsp report formnbspk fontdivnbspdiv table width border cellpadding cellspace widthtd widthtd valigntop tdbfont sizeitem fontbtd bfont sizechange disagreement accountant account financial disclosurefontbtd table alignleftnbspnbspnbspnbspnbsp font sizenot applicable font divnbspdiv table width border cellpadding cellspace widthtd widthtd valigntop tdbfont sizeitemnbspafontbtd bfont sizenbspnbspnbspnbspnbspcontrol proceduresfontbtd table alignleftnbspnbspnbspnbspnbsp ifont sizedisclosure control proceduresfontifont size end fiscal fourth quarter company evaluate effectiveness design operation disclosure control procedure company disclosure control procedure design ensure information require disclose company report file submit securities exchange act record process summarize report time period specify sec rule form disclosure control procedure include limitation control procedure design ensure information require disclose company report file submit securities exchange act accumulate communicate company management include principal executive principal financial officer person perform similar function appropriate allow timely decision require disclosure williamnbspc weldon chairman chief executive officer robertnbspj darretta vice chairman chief financial officer review participate evaluation base evaluation messrsnbspweldon darretta conclude date evaluation company disclosure control procedure effective font alignleftnbspnbspnbspnbspnbsp ifont sizeinternal controlfontifont size management report internal control financial reporting include report formnbspk item fiscal quarter end januarynbsp change companys internal control financial reporting materially affect reasonably likely materially affect company internal control financial reporting font alignleftnbspnbspnbspnbspnbsp ifont sizemanagement report internal control financial reporting fontifont sizeundersection sarbanesoxley act management require assess effectiveness company internal control financial reporting end fiscal year report base assessment company internal control financial reporting effective font alignleftnbspnbspnbspnbspnbsp font sizemanagement company responsible establish maintain adequate internal control financial reporting company internal control financial reporting design provide reasonable assurance reliability company financial reporting preparation financial statement accordance generally accept accounting principle font alignleftnbspnbspnbspnbspnbsp font sizeinternal control financial reporting matter design inherent limitation internal control financial reporting determine effective provide reasonable assurance respect financial statement preparation prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate font aligncenterfont size font pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp alignleftnbspnbspnbspnbspnbsp font sizethe companys management assess effectiveness company internal control financial reporting januarynbsp make assessment company criterion establish committee sponsor organization treadway commission coso internal controlintegrate framework criterion area control environment risk assessment control activity information communication monitoring company assessment include extensive documenting evaluating testing design operating effectiveness internal control financial reporting font alignleftnbspnbspnbspnbspnbsp font sizebase company process assessment describe management conclude januarynbsp company internal control financial reporting effective font alignleftnbspnbspnbspnbspnbsp font sizemanagement assessment effectiveness company internal control financial reporting januarynbsp audit pricewaterhousecooper llp independent register public accounting firm state report appear report independent register public accounting firm nbsp annual report incorporate reference file exhibitnbsp report formnbspk font alignleft bfont sizeitem bnbspnbspnbspnbspnbspother informationfontb alignleftnbspnbspnbspnbspnbsp font sizeon marchnbsp company announce board director approve stock repurchase program authorize company buy nbspbillion company common stock repurchase place open market timetotime base market condition therepurchase program time limit suspend period discontinue font aligncenter bfont sizepart iiifontb alignleft bfont sizeitem nbspnbspdirector executive officer registrantfontb alignleftnbspnbspnbspnbspnbsp font sizethe information call item incorporate reference anbspthe material caption election directorsnbsp nominee nbspother information page proxy statement bnbspthe material hereof caption executive officer registrant cnbspthe discussion audit committee head director fee committee meeting pagesnbsp proxy statement dnbspthe material caption sectionnbspa beneficial ownership report compliance nbsp proxy statement font alignleftnbspnbspnbspnbspnbsp font sizethe companys policy business conduct cover employee include chief executive officer chief financial officer controller meet requirement sec rule promulgate sectionnbsp sarbanesoxley act policy business conduct available company web site iwwwinvestorjnjcomgovernancei copy available shareholder charge write request secretary company principal address substantive amendment policy business conduct waiver policy grant chief executive officer chief financial officer controller post company web site iwwwinvestorjnjcomgovernancei business day retain web site year font alignleftnbspnbspnbspnbspnbsp font sizein addition company adopt code business conduct ethic member board director executive officer code business conduct ethic member board director executive officer available company web site iwwwinvestorjnjcomgovernancei copy available shareholder charge write request secretary company principal address substantive amendment code waiver code grant member board director executive officer post company web site iwwwinvestorjnjcomgovernancei business day retain web site year font alignleft bfont sizeitem nbspnbspexecutive compensationfontb alignleftnbspnbspnbspnbspnbsp font sizethenbspinformation call item incorporate reference follow section proxy statement election directorsnbsp director fee committee meeting pagesnbsp compensationnbsp benefit committee report executive compensation pagesnbsp font aligncenterfont size font pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphpdiv alignleft font size shareholder return performance graph pagesnbsp executive compensation pagesnbsp font div divnbspdiv table width border cellpadding cellspace widthtd widthtd valigntop tdbfont sizeitem fontbtd bfont sizesecurity ownership certain beneficial owner management relate stockholder mattersfontbtd table alignleftnbspnbspnbspnbspnbsp font sizethe information call item incorporate reference material caption election directorsnbsp stock ownershipcontrol nbsp proxy statement notenbsp note consolidated financial statement nbsp annual report file exhibitnbsp report formnbspk font alignleft bfont sizeequity compensation plan informationfontb alignleftnbspnbspnbspnbspnbsp font sizethe follow table provide certain information january concern share company common stock issue exist equity compensation plan font center table width aligncenter cellspace cellpadde border widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd tdtd tdtd colspan aligncenter nowrapbfont sizenumber shares befontbtd tdtd colspan aligncenter nowrapbfont sizeweighte averagefontbtd tdtd colspan aligncenter nowrapbfont sizenumber sharesfontbtd tdtd tdtd colspan aligncenter nowrapbfont sizeissue exercise offontbtd tdtd colspan aligncenter nowrapbfont sizeexercise pricefontbtd tdtdtd colspan aligncenter nowrapbfont sizeremaine available forfontbtd tdtd tdtd colspan aligncenter nowrapbfont sizeoutstanding optionsfontbtd tdtd colspan aligncenter nowrapbfont sizeof outstandingfontbtd tdtd colspan aligncenter nowrapbfont sizefuture issuance underfontbtd tdtd tdtd colspan aligncenter nowrapbfont sizeand rightsfontbtd tdtd colspan aligncenter nowrapbfont sizeoption rightsfontbtd tdtd colspan aligncenter nowrapbfont sizeequity compensation plansfontbtd tdtd tdtd colspan aligncenter nowrapbfont sizeasnbspofnbspjannbspnbspfontb tdtd colspan aligncenter nowrapbfont sizeasnbspofnbspjannbspnbspfontb tdtd colspan aligncenter nowrapbfont sizeasnbspofnbspjannbspnbspfontb supfont sizefontsuptd tdtd tdtd colspan aligncenter nowraphr size noshadetd tdtd colspan aligncenter nowraphr size noshadetd tdtd colspan aligncenter nowraphr size noshadetd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizeequity compensation plan approve shareholderssupsup fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizefonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeequity compensation plan approve shareholderssupsup fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizefonttd alignright valignbottom nowrapfont sizefonttdtdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizetotal fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizefonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd table center alignleft size width alignleft colorblack noshade table width border cellpadding cellspace widthtd widthtd valigntop tdsupfont sizefontsupfont sizenbspfonttd alignleft font sizeincluded category follow equity compensation plan approve company shareholder stock option plan stock option plan stock compensation plan long term incentive plan fonttd table table width border cellpadding cellspace widthtd widthtd valigntop tdsupfont sizenbspfontsuptd alignleft font sizeincluded category nbspshare common stock issuable equity compensation plan assume company acquisition follow company alza corporation sciosnbspinc biosensenbspinc innovasive devicesnbspinc inverness medical technologynbspinc centocornbspinc share list issuable category issue plan approve shareholder company prior acquisition assumption plan company time acquisition option acquire equity acquire company replace option acquire common stock company stock option equity award type plan assumption plan company stock option equity award type underany plan future fonttd table table width border cellpadding cellspace widthtd widthtd valigntop tdnbsptd alignleft font sizethe share include column issue plan approve shareholder applicable acquire company nbspshare issuable biosense stock option plan nbspshare issuable scio nonofficer stock option plan nbspshare issuable alza nonstatutory plan nbspshare issuable warrant inverness medical plan fonttd table table width border cellpadding cellspace widthtd widthtd valigntop tdsupfont sizenbspfontsuptd alignleft font sizealso include category nbspshare common stock issuable exercise outstanding stock option companys stock option plan nonemployee director fonttd tdnbsptd valigntop tdsupfont sizenbspfontsuptd alignleft font sizethis column exclude share reflect column number share issue exercise outstanding option right jannbspnbsp fonttd table alignleft bfont sizeitem nbspnbspcertain relationship relate transactionsfontb alignleftnbspnbspnbspnbspnbsp font sizethe information call item incorporate reference material caption election directorsnbsp certain business relationship nbsp proxy statement font aligncenterfont size font pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphpp alignleft bfont sizeitem nbspnbspprincipal accounting fee servicesfontb alignleftnbspnbspnbspnbspnbsp font sizethe information call item incorporate reference material heading ratification appointment independent register public accounting firm preapproval audit nonaudit services pagesnbsp proxy statement font aligncenter bfont sizepart ivfontb alignleft bfont sizeitem nbspnbspexhibit financial statement schedulesfontb alignleftnbspnbspnbspnbspnbsp font sizeanbspthe follow document file report font alignleftnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font sizeinbspfinancial statementsi font alignleftnbspnbspnbspnbspnbsp font sizethe follow audit consolidated financial statement note thereto report independent register public accounting firm page annual report incorporate reference file exhibitnbsp report formnbspk font alignleftnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font sizeconsolidate balance sheet end fiscal year font alignleftnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font sizeconsolidate statement earning fiscal year font alignleftnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font sizeconsolidate statement equity fiscal year font alignleftnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font sizeconsolidate statement cash flow fiscal year nbspnbspnbspnbspnbspnbspnbspnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font alignleftnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font sizenote consolidate financial statement font alignleftnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font sizereport independent register public accounting firm font alignleftnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font sizenbspifinancial statement schedulesi font alignleftnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font sizeschedule iinbsp valuation qualifying account font alignleftnbspnbspnbspnbspnbsp font sizeschedule list omit require applicable fontp alignleftnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font sizenbspiexhibit require file item regulation ski font alignleftnbspnbspnbspnbspnbsp font sizethe information call item incorporate reference exhibit index report font aligncenterfont size font pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp aligncenter bfont sizejohnson johnson subsidiariesfontb aligncenter bfont sizeschedule iinbsp valuation qualifying accountsfontb aligncenter bfont sizefiscal year end januarynbsp januarynbsp decembernbsp fontb div aligncenter bfont sizedollar millionsfontb div center table width aligncenter cellspace cellpadde border widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd tdtd tdtd colspan aligncenter nowrapbfont sizebalance atfontbtd tdtd colspantd tdtd colspantd tdtd colspan aligncenter nowrapbfont sizebalance atfontbtd tdtd tdtd colspan aligncenter nowrapbfont sizebeginningfontbtd tdtd colspantd tdtd colspan aligncenter nowrapbfont sizepaymentsfontbtd tdtd colspan aligncenter nowrapbfont sizeend offontbtd trtr tdtd tdtd colspan aligncenter nowrapbfont sizeof periodfontbtd tdtd colspan aligncenter nowrapbfont sizeaccrualsfontbtd tdtd colspan aligncenter nowrapbfont sizeotherfontbtd tdtd colspan aligncenter nowrapbfont sizeperiodfontbtd tdtd tdtd colspan aligncenter nowraphr size noshadetd tdtd colspan aligncenter nowraphr size noshadetd tdtd colspan aligncenter nowraphr size noshadetd tdtd colspan aligncenter nowraphr size noshadetd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font size fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeaccrue rebate return promotionssupsup fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizefonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd alignleft valignbottom nowrapsupfont sizefontsuptd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizereserve doubtful account fontdiv tdfont sizenbspfonttdtd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizereserve cash discount fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizefonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd trtr tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font size fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizeaccrue rebate return promotionssupsup fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizefonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd alignleft valignbottom nowrapsupfont sizefontsuptd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizereserve doubtful account fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttdtdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizereserve cash discount fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizefonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttdtdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font size fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeaccrue rebate return promotionssupsup fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizefonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizereserve doubtful account fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttdtdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizereserve cash discount fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizefonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetdtdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd table center div alignleft size width alignleft colorblack noshade div table width border cellpadding cellspace widthtd widthtd valigntop tdsupfont sizenbspfontsuptd alignleft font sizeinclude reserve customer rebate million million million januarynbsp januarynbsp decembernbsp respectively fonttd tdnbsptd valigntop tdsupfont sizenbspfontsuptd alignleft font sizeinclude nbspmillion relate previously estimate performancebase rebate allowance manage care contract fonttd tdnbsptd valigntop tdsupfont sizenbspfontsuptd alignleft font sizeinclude million relate previously estimate performancebase rebate allowance manage care contract fonttd table aligncenterfont size font pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp aligncenter bfont sizesignaturesfontb alignleftnbspnbspnbspnbspnbsp font sizepursuant requirement section securities exchange act registrant duly causedthis report sign behalf undersigned thereunto duly authorize font alignleft font sizedate marchnbsp font table width border cellpadding cellspace widthtd widthtd valigntop tdnbsptd aligncenter font sizejohnson johnson fonttd valigntop tdnbsptd alignleft size alignleft colorblack noshadetd valigntop tdnbsptd aligncenter font sizeregistrant fonttd table table width border cellpadding cellspace widthtd widthtd widthtd valigntop tdnbsptd tdfont sizebynbspfonttd alignleft font sizesw weldon fonttd table table width border cellpadding cellspace widthtd widthtd valigntop tdnbsptd alignleft size alignleft colorblack noshadetd valigntop tdnbsptd aligncenter font sizew weldon chairman board director fonttd valigntop tdnbsptd aligncenter font sizeand chief executive officer fonttdtr table table width border cellpadding cellspace widthtd widthtd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizepursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate fonttd table center table width aligncenter cellspace cellpadde border widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd aligncenter nowrapbfont sizesignaturefontbtd tdtd aligncenter nowrapbfont sizetitlefontbtd tdtd aligncenter nowrapbfont sizedatefontbtd aligncenter nowraphr size noshadetd tdtd aligncenter nowraphr size noshadetd tdtd aligncenter nowraphr size noshadetd colspanfont sizenbspfonttd alignleft valigntop font size weldonbr size noshadew weldon fonttd tdfont sizenbspfonttd alignleft valigntop font sizechairman board directorsbr chief executive officer director principal executive officer fonttd tdfont sizenbspfonttd alignleft valigntop font sizemarchnbsp fonttd colspanfont sizenbspfonttd colspanfont sizenbspfonttd trtd alignleft valigntop font size darrettabr size noshader darretta fonttd tdfont sizenbspfonttd alignleft valigntop font sizevice chairman board director chief financial officer director principal financial officer fonttd tdfont sizenbspfonttd alignleft valigntop font sizemarchnbsp fonttd colspanfont sizenbspfonttd alignleft valigntop font size poonbr size noshadec poon fonttd tdfont sizenbspfonttd alignleft valigntop font sizevice chairman board director director fonttd tdfont sizenbspfonttd alignleft valigntop font sizemarchnbsp fonttd colspanfont sizenbspfonttd alignleft valigntop font size cosgrovebr size noshade cosgrove fonttd tdfont sizenbspfonttd alignleft valigntop font sizecontroller fonttd tdfont sizenbspfonttd alignleft valigntop font sizemarchnbsp fonttd colspanfont sizenbspfonttd alignleft valigntop font size colemanbr size noshadem coleman fonttd tdfont sizenbspfonttd alignleft valigntop font sizedirector fonttd tdfont sizenbspfonttd alignleft valigntop font sizemarchnbsp fonttd colspanfont sizenbspfonttd alignleft valigntop font size cullenbr size noshadej cullen fonttdtdfont sizenbspfonttd alignleft valigntop font sizedirector fonttd tdfont sizenbspfonttd alignleft valigntop font sizemarchnbsp fonttd colspanfont sizenbspfonttd alignleft valigntop font size johnsbr size noshadem johns fonttd tdfont sizenbspfonttd alignleft valigntop font sizedirector fonttd tdfont sizenbspfonttd alignleft valigntop font sizemarchnbsp fonttd colspanfont sizenbspfonttd alignleft valigntop font size jordanbr size noshadea jordan fonttd tdfont sizenbspfonttd alignleft valigntop font sizedirector fonttd tdfont sizenbspfonttd alignleft valigntop font sizemarchnbsp fonttd colspanfont sizenbspfonttd alignleft valigntop font size langbobr size noshadea langbo fonttd tdfont sizenbspfonttd alignleft valigntop font sizedirector fonttd tdfont sizenbspfonttd alignleft valigntop font sizemarchnbsp fonttd colspanfont sizenbspfonttd table center aligncenterfont size font pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphpcenter table width aligncenter cellspace cellpadde border widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd aligncenter nowrapbfont sizesignaturefontbtd tdtd aligncenter nowrapbfont sizetitlefontbtd tdtd aligncenter nowrapbfont sizedatefontbtd aligncenter nowraphr size noshadetd tdtd aligncenter nowraphr size noshadetd tdtd aligncenter nowraphr size noshadetd alignleft valigntop font size lindquistbr size noshade lindquist fonttd tdfont sizenbspfonttd alignleft valigntop font sizedirector fonttd tdfont sizenbspfonttd alignleft valigntop font sizemarchnbsp fonttd colspanfont sizenbspfonttd alignleft valigntop font size mullinbr size noshadelf mullin fonttd tdfont sizenbspfonttd alignleft valigntop font sizedirector fonttd tdfont sizenbspfonttd alignleft valigntop font sizemarchnbsp fonttd colspanfont sizenbspfonttd alignleft valigntop font size princebr size noshadec prince fonttd tdfont sizenbspfonttd alignleft valigntop font sizedirector fonttd tdfont sizenbspfonttd alignleft valigntop font sizemarchnbsp fonttd trtd colspanfont sizenbspfonttd alignleft valigntop font size reinemundbr size noshade reinemund fonttd tdfont sizenbspfonttd alignleft valigntop font sizedirector fonttd tdfont sizenbspfonttd alignleft valigntop font sizemarchnbsp fonttd colspanfont sizenbspfonttd alignleft valigntop font size satcherbr size noshade satcher fonttd tdfont sizenbspfonttd alignleft valigntop font sizedirector fonttd tdfont sizenbspfonttd alignleft valigntop font sizemarchnbsp fonttd colspanfont sizenbspfonttd table center aligncenterfont size font pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp aligncenter bfont sizereport independent register public accounting firm onfontb div aligncenter bfont sizefinancial statement schedulefontb div alignleft font sizeto board director font div alignleft font sizejohnson johnson font div alignleftnbspnbspnbspnbspnbsp font sizeour audits consolidated financial statement management assessment effectiveness internal control financial reporting effectiveness internal control financial reporting refer report date februarynbsp appear annual report shareholder johnson johnson report consolidated financial statement assessment incorporate reference annual report formnbspk include audit financial statement schedule list itemnbspa formnbspk opinion financial statement schedule present fairly material respect theinformation set forth read conjunction relate consolidated financial statement font alignleft font size pricewaterhousecooper llp font div alignleft size width alignleft colorblack noshade div div alignleft font sizepricewaterhousecooper llp font div alignleft font sizenew york new york font div alignleft font sizefebruarynbsp font div aligncenterfont size font pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp aligncenter bfont sizeexhibit indexfontb center table width aligncenter cellspace cellpadde border widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd colspan aligncenter nowrapbfont sizereg skfontbtd tdtd tdtd colspan aligncenter nowrapbfont sizeexhibit tablefontbtd tdtd aligncenter nowrapbfont sizedescriptionfontbtd colspan aligncenter nowrapbfont sizeitem nofontbtd tdtd aligncenter nowrapbfont sizeof exhibitfontbtd colspan aligncenter nowraphr size noshadetd tdtd aligncenter nowraphr size noshadetd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizeaifonttd tdfont sizenbspfonttd alignleft valigntop font sizerestate certificate incorporation date aprilnbsp nbsp incorporate reference exhibitnbspa registrants formnbspk annual report year end decembernbsp fonttdtr alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizeaiifonttd tdfont sizenbspfonttd alignleft valigntop font sizecertificate amendment restate certificate incorporation company date maynbsp nbsp incorporate reference exhibitnbspa registrants formnbspk annual report year end januarynbsp fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizeaiiifonttd tdfont sizenbspfonttd alignleft valigntop font sizecertificate amendment restate certificate incorporation company date maynbsp nbsp incorporate reference exhibitnbspaiii registrant formnbspk annual report year end decembernbsp fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizeaivfonttd tdfont sizenbspfonttd alignleft valigntop font sizecertificate amendment restate certificate incorporation company effective maynbsp nbsp incorporate reference exhibitnbsp registrant formnbspq quarterly report quarter end julynbsp fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizebfonttd tdfont sizenbspfonttd alignleft valigntop font sizebylaw company amend effective junenbsp nbsp incorporate reference exhibitnbsp registrant formnbspq quarterly report quarter end julynbsp fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizeafonttd tdfont sizenbspfonttd alignleft valigntop font sizeupon request security exchange commission registrant furnish copy instrument define right holder long term debt registrant fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizeafonttd tdfont sizenbspfonttd alignleft valigntop font sizestock option plan nonemployee directorsnbsp incorporate reference exhibitnbspa registrants formnbspk annual report year end decembernbsp fonttdtr alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizebfonttd tdfont sizenbspfonttd alignleft valigntop font size stock option plan amendednbsp incorporate reference exhibitnbspb registrant formnbspk annual report year end decembernbsp fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizecfonttd tdfont sizenbspfonttd alignleft valigntop font size stock option plan amendednbsp incorporate reference exhibitnbspb registrant formnbspk annual report year end januarynbsp fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizedfonttd tdfont sizenbspfonttd alignleft valigntop font size stock compensation plannbsp incorporate reference exhibitnbspe registrant formnbspk annual report year end decembernbsp fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizeefonttd tdfont sizenbspfonttd alignleft valigntop font size longterm incentive plannbspnbspincorporate reference exhibitnbsp registrant registration statement file commission maynbsp file nonbsp fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizeffonttd tdfont sizenbspfonttd alignleft valigntop font sizeform stock option certificate restrict share nonemployee director certificate longterm incentive plannbsp incorporate reference exhibitnbsp registrant formnbspq quarterly report quarter end julynbsp fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizegfonttd tdfont sizenbspfonttd alignleft valigntop font sizeform restrict stock unit certificate longterm incentive plannbsp incorporate reference exhibitnbsp registrant formnbspq quarterly report quarter end octobernbsp fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizehfonttd tdfont sizenbspfonttd alignleft valigntop font sizeexecutive bonus plannbsp incorporate reference exhibitnbsp registrant formnbsp registration statement file commission novembernbsp file nonbsp fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizeifonttd tdfont sizenbspfonttd alignleft valigntop font sizeexecutive incentive plan amendednbsp incorporate reference exhibitnbspf registrants formnbspk annual report year end decembernbsp fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizejfonttd tdfont sizenbspfonttd alignleft valigntop font sizedomestic defer compensation certificate extra compensation plan amendednbsp incorporate reference exhibitnbspg registrant formnbspk annual report year end decembernbsp fonttd table center aligncenterfont size font pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp center table width aligncenter cellspace cellpadde border widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd colspan aligncenter nowrapbfont sizereg skfontbtd tdtd tdtd colspan aligncenter nowrapbfont sizeexhibit tablefontbtd tdtd aligncenter nowrapbfont sizedescriptionfontbtd colspan aligncenter nowrapbfont sizeitem nofontbtd tdtd aligncenter nowrapbfont sizeof exhibitfontbtd trtr colspan aligncenter nowraphr size noshadetd tdtd aligncenter nowraphr size noshadetd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizekfonttd tdfont sizenbspfonttd alignleft valigntop font sizedeferre fee plan nonemployee director amend incorporate reference exhibitnbsph registrants formnbspk annual report year end januarynbsp fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizelfonttd tdfont sizenbspfonttd alignleft valigntop font sizeexecutive income deferral plan amendednbsp incorporate reference exhibitnbspi registrants formnbspk annual report year end decembernbsp fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizemfonttd tdfont sizenbspfonttd alignleft valigntop font sizeexcess saving plannbsp incorporate reference exhibitnbspj registrant formnbspk annual report year end decembernbsp fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizenfonttd tdfont sizenbspfonttd alignleft valigntop font sizesupplemental retirement plan incorporate reference exhibit registrant annual report year end januarynbsp fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizeofonttd tdfont sizenbspfonttd alignleft valigntop font sizeexecutive life insurance plan incorporate reference exhibit inbspof registrant annual report year end januarynbsp fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizepfonttd tdfont sizenbspfonttd alignleft valigntop font sizestock option gain deferral plannbsp incorporate reference exhibitnbspm registrants formnbspk annual report year end januarynbsp fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizeqfonttd tdfont sizenbspfonttd alignleft valigntop font sizeestate preservation plannbsp incorporate reference exhibitnbspn registrants formnbspk annual report year end januarynbsp fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizerfonttd tdfont sizenbspfonttd alignleft valigntop font sizesummary employment arrangement michaelnbspj dormernbsp file document fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizesfonttd tdfont sizenbspfonttd alignleft valigntop font sizesummary compensation arrangement name executive officer director file document fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizestatement computation ratio earning fix charge file document fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizenbsppage company annual report shareholder fiscal year portion annual report incorporate reference report deem file file document fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizesubsidiarie file document fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizeconsent independent register publicaccounte firmnbsp file document fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizeafonttd tdfont sizenbspfonttd alignleft valigntop font sizecertification chief executive officer pursuant sectionnbsp sarbanesoxley act nbsp file document fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizebfonttd tdfont sizenbspfonttd alignleft valigntop font sizecertification chief financial officer pursuant sectionnbsp sarbanesoxley act nbsp file document fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizeafonttd tdfont sizenbspfonttd alignleft valigntop font sizecertification chief executive officer pursuant sectionnbsp sarbanesoxley act nbsp furnish document fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd alignleft valigntop nowrapfont sizebfonttd tdfont sizenbspfonttd alignleft valigntop font sizecertification chief financial officer pursuant sectionnbsp sarbanesoxley act nbsp furnish document fonttd alignright valigntopfont sizenbspfonttd alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop font sizecautionary statement pursuant private security litigation reform act nbsp safe harbor forwardlooke statement file document fonttd table center div alignleft size width alignleft colorblack noshade div table width border cellpadding cellspace widthtd widthtd valigntoptdfont sizenbspfonttd alignleft font sizemanagement contract compensatory plan fonttd table alignleftnbspnbspnbspnbspnbsp font sizea copy exhibit list provide charge shareholder submit write request specify desire exhibit secretary principal executive office company font aligncenterfont size font body html text document document typeexr sequence filenameyexvwrhtm descriptionexr summary employment arrangement michael dormer text html head titleexrtitle head body bgcolorffffff pagebreak alignleft stylebreakbeforealwaysnbsphp div stylewidth marginleft begin logical div alignright stylemarginleft marginright fontsize fontfamily arial helvetica color background ffffff bfont stylefontfamily time new roman timesexhibitrfontb div div stylemargintop fontsize ptnbspdiv div aligncenter stylemarginleft marginright fontsize fontfamily arial helvetica color background ffffff bfont stylefontfamily time new roman timessummary employment arrangement michael dormerfontb div div stylemargintop fontsize ptnbspdiv div alignleft stylemarginleft marginright textindent fontsize fontfamily time new roman time color background ffffff certain arrangement benefit place mrmichael dormer worldwide chairman medical device member executive committee arise prior employment chief operating officer depuy inc johnson johnson acquire depuy mrdormer offer employment agreement replace exist employment agreement depuy inc mrdormer company agree rescind employment agreement appoint executive committee name franchise group chairman medical device certain benefit arrangement mrdormer employment agreement retain follow arrangement benefit place continue available mrdormer div div stylemargintop fontsize ptnbspdiv table width border cellpadding cellspace widthtd widthtd widthtdtr valigntop stylefontsize fontfamily time new roman time color background ffffff tdnbsptd alignleft mrdormer terminate reason cause receive severance pay equal great year compensation base average previous year base salary bonus company severance pay policy stylelineheight fontsize pttdnbsptdtr valigntop stylefontsize fontfamily time new roman time color background ffffff tdnbsptd alignleft mrdormer pension benefit cover preacquisition service depuy inc stylelineheight fontsize pttdnbsptdtr valigntop stylefontsize fontfamily time new roman time color background ffffff tdnbsptd alignleft retirement involuntary termination employment company pay relocation cost associate mrdormer relocation united kingdom pursuant company relocation policy event mrdormer die reside united states employment company provide relocation assistance family relocation united kingdom include manage sale home united states stylelineheight fontsize pttdnbsptdtr valigntop stylefontsize fontfamily time new roman time color background ffffff tdnbsptd alignleft company fund term life insurance policy benefit mrdormer family offset negative estate tax implication mrdormer spouse die reside united states employment company table div body html text document document typeexs sequence filenameyexvwshtm descriptionexs summary compensation arrangement text html head titleexstitlehead body bgcolorffffff pagebreak alignleft stylebreakbeforealwaysnbsphp div stylewidth marginleft begin logical div alignright stylemarginleft marginright fontsize fontfamily arial helvetica color background ffffff bfont stylefontfamily time new roman timesexhibitsfontb div div stylemargintop fontsize ptnbspdiv div aligncenter stylemarginleft marginright fontsize fontfamily arial helvetica color background ffffff bfont stylefontfamily time new roman timessummary compensation arrangement forbr name executive officer directorsfontb div div stylemargintop fontsize ptnbspdiv div alignleft stylemarginleft marginright fontsize fontfamily arial helvetica color background ffffff bfont stylefontfamily time new roman timescompensation arrangement name executive officersfontb div div stylemargintop fontsize ptnbspdiv div alignleft stylemarginleft marginright textindent fontsize fontfamily time new roman time color background ffffff follow description compensation arrangement approve compensation benefit committee board directors johnson johnson compensation committee february company chief executive officer highly compensate executive officer name executive officer div div stylemargintop fontsize ptnbspdiv div alignleft stylemarginleft marginright fontsize fontfamily arial helvetica color background ffffff bifont stylefontfamily time new roman timesannual base salaryfontib div div stylemargintop fontsize ptnbspdiv div alignleft stylemarginleft marginright textindent fontsize fontfamily time new roman time color background ffffff compensation committee approve follow base salary effective february name executive officer div div stylemargintop fontsize ptnbspdiv table border width aligncenter cellpadde cellspace stylefontsize font family time new roman time color background ffffff table width row stylefontsize valignbottom widthnbsptd colindex typemaindata widthnbsptd colindex typegutter width alignrightnbsptd colindex typelead width alignrightnbsptd colindex typebody width alignleftnbsptd colindex typehang valignbottom stylebackground cceeff alignleft valignbottom div styletextindent marginleft font stylefontsize ptwilliam weldon font divtd nbsp nowrap alignright valignbottom nowrap alignleft valignbottom nowrap alignleft valignbottom nbsp valignbottom nowrap alignleft valignbottom div styletextindent marginleft font stylefontsize ptchairmanceo font div nbsp nowrap alignleft valignbottom nbsp nowrap alignright valignbottom nbsp nowrap alignleft valignbottom nbsp valignbottom alignleft valignbottom div styletextindent marginleft font stylefontsize ptnbsp font div nbsp nowrap alignright valignbottom nbsp nowrap alignleft valignbottom nbsp nowrap alignleft valignbottom nbsp valignbottom stylebackground cceeff alignleft valignbottom div styletextindent marginleft font stylefontsize ptrobert darretta font div nbsp nowrap alignright valignbottom nowrap alignleft valignbottom nowrap alignleft valignbottom nbsp valignbottom nowrap alignleft valignbottom div styletextindent marginleft font stylefontsize ptvice chairmancfofont div nbsp nowrap alignleft valignbottom nbsp nowrap alignright valignbottom nbsp nowrap alignleft valignbottom nbsp valignbottom alignleft valignbottom div styletextindent marginleft font stylefontsize ptnbsp font div nbsp nowrap alignright valignbottom nbsp nowrap alignleft valignbottom nbsp nowrap alignleft valignbottom nbsp valignbottom stylebackground cceeff alignleft valignbottom div styletextindent marginleft font stylefontsize ptchristine poon font div nbsp nowrap alignright valignbottom nowrap alignleft valignbottom nowrap alignleft valignbottom nbsp valignbottom alignleft valignbottom div styletextindent marginleft font stylefontsize ptvice chairmanworldwide chairman medicine nutritional font div nbsp nowrap alignleft valignbottom nbsp nowrap alignright valignbottom nbsp nowrap alignleft valignbottom nbsp valignbottom alignleft valignbottom div styletextindent marginleft ptfont stylefontsize ptnbsp font div nbsp nowrap alignright valignbottom nbsp nowrap alignleft valignbottom nbsp nowrap alignleft valignbottom nbsp valignbottom stylebackground cceeff alignleft valignbottom div styletextindent marginleft font stylefontsize ptmichael dormer font div nbsp nowrap alignright valignbottom nowrap alignleft valignbottom nowrap alignleft valignbottom nbsp valignbottom alignleft valignbottom div styletextindent marginleft font stylefontsize ptworldwide chairman medical device font div nbsp nowrap alignleft valignbottom nbsp nowrap alignright valignbottom nbsp nowrap alignleft valignbottom nbsp valignbottom alignleft valignbottom div styletextindent marginleft font stylefontsize ptnbsp font div nbsp nowrap alignright valignbottom nbsp nowrap alignleft valignbottom nbsp nowrap alignleft valignbottom nbsp valignbottom stylebackground cceeff alignleft valignbottomdiv styletextindent marginleft font stylefontsize ptper peterson font div nbsp nowrap alignright valignbottom nowrap alignleft valignbottom nowrap alignleft valignbottom nbsp valignbottom alignleft valignbottom div styletextindent marginleft font stylefontsize ptchairman pharmaceutical group font div nbsp nowrap alignleft valignbottom nbsp nowrap alignright valignbottom nbsp nowrap alignleft valignbottom nbsp table div alignleft stylemarginleft marginright textindent fontsize fontfamily time new roman time color background ffffff div div stylemargintop fontsize ptnbspdiv div alignleft stylemarginleft marginright fontsize fontfamily arial helvetica color background ffffff bifont stylefontfamily time new roman timesbonusfontib div div stylemargintop fontsize ptnbspdiv div alignleft stylemarginleft marginright textindent fontsize fontfamily time new roman time color background ffffff compensation committee approve follow bonus payment performance divide discretion compensation committee cash fair market value common stock awards february div div stylemargintop fontsize ptnbspdiv table border width aligncenter cellpadde cellspace stylefontsize font family time new roman time color background ffffff table width row stylefontsize valignbottom widthnbsptd colindex typemaindata widthnbsptd colindex typegutter widthnbsptd colindex typemaindata widthnbsptd valignbottom stylebackground cceeff nowrap alignleft valignbottom div styletextindent marginleft font stylefontsize ptmrweldon font divtd nbsp nowrap alignleft valignbottom valignbottom nowrap alignleft valignbottom div styletextindent marginleft font stylefontsize ptmrdarretta font div nbsp nowrap alignleft valignbottom valignbottom stylebackground cceeff nowrap alignleft valignbottom div styletextindent marginleft font stylefontsize ptmspoon font div nbsp nowrap alignleft valignbottom valignbottom nowrap alignleft valignbottom div styletextindent marginleft font stylefontsize ptmrdormer font div nbsp nowrap alignleft valignbottom valignbottom stylebackground cceeff nowrap alignleft valignbottom div styletextindent marginleft font stylefontsize ptdrpeterson font div nbsp nowrap alignleft valignbottom table div alignleft stylemarginleft marginright textindent fontsize fontfamily time new roman time color background ffffff div div stylemargintop fontsize ptnbspdiv div alignleft stylemarginleft marginright fontsize fontfamily arial helvetica color background ffffff bifont stylefontfamily time new roman timesstock option restrict share unit grantsfontib div div stylemargintop fontsize ptnbspdivdiv alignleft stylemarginleft marginright textindent fontsize fontfamily time new roman time color background ffffff compensation committee approve follow stock option restrict share unit rsu grant companys longterm incentive plan stock option grant exercise price fair market value company common stock date grant option exercisable february div aligncenterfont stylefontsize ptfont div pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp div stylewidth marginleft begin logical div alignleft stylemarginleft marginright textindent fontsize fontfamily time new roman time color background ffffff expire february rsus grant fair market value company common stock date grant rsus vest february rsu holder employ company date receive share company common stock div div stylemargintop fontsize ptnbspdiv table border width aligncenter cellpadde cellspace stylefontsize font family time new roman time color background ffffff table width row stylefontsize valignbottom widthnbsptd colindex typemaindata widthnbsptd colindex typegutter widthnbsptd colindex typemaindata widthnbsptd colindex typegutter widthnbsptd colindex typemaindata widthnbsptd valignbottom stylebackground cceeff nowrap alignleft valignbottom div styletextindent marginleft font stylefontsize ptmrweldon fontdivtd tdnbsptd alignleft valignbottom font stylefontsize stock option fonttd tdnbsptd nowrap alignleft valignbottom font stylefontsize rsus fonttd valignbottom nowrap alignleft valignbottom div styletextindent marginleft font stylefontsize ptmrdarretta font div nbsp alignleft valignbottom font stylefontsize stock option font nbsp nowrap alignleft valignbottom font stylefontsize rsus font valignbottom stylebackground cceefftd nowrap alignleft valignbottom div styletextindent marginleft font stylefontsize ptmspoon font div nbsp alignleft valignbottom font stylefontsize stock option font nbsp nowrap alignleft valignbottom font stylefontsize rsus font valignbottom nowrap alignleft valignbottom div styletextindent marginleft font stylefontsize ptmrdormer font div nbsp alignleft valignbottom font stylefontsize stock option font nbsp nowrap alignleft valignbottom font stylefontsize rsus font valignbottom stylebackground cceeff nowrap alignleft valignbottom div styletextindent marginleft font stylefontsize ptdrpeterson font div nbsp alignleft valignbottom font stylefontsize stock option font nbsp alignleft valignbottom font stylefontsize rsus font table div alignleft stylemarginleft marginright textindent fontsize fontfamily time new roman time color background ffffff div div stylemargintop fontsize ptnbspdiv div alignleft stylemarginleft marginright fontsize fontfamily arial helvetica color background ffffff bifont stylefontfamily time new roman timeslong term incentive plan awardsfontib divdiv stylemargintop fontsize ptnbspdiv div alignleft stylemarginleft marginright textindent fontsize fontfamily time new roman time color background ffffff compensation committee approve follow longterm incentive plan awards february recognition performance company certificate extra compensation cec program award pay retirement termination employment end fiscal year cec value unit value cec unit preliminary subject increase decrease base performance company div div stylemargintop fontsize ptnbspdiv table border width aligncenter cellpadde cellspace stylefontsize font family time new roman time color background ffffff table width row stylefontsize valignbottom widthnbsptd colindex typemaindata widthnbsptd colindex typegutter widthnbsptd colindex typemaindata widthnbsptd valignbottom stylebackground cceeff nowrap alignleft valignbottom div styletextindent marginleft font stylefontsize ptmrweldon font div nbsp alignleft valignbottom font stylefontsize cec unit font valignbottom nowrap alignleft valignbottom div styletextindent marginleft font stylefontsize ptmrdarretta font div nbsp alignleft valignbottom font stylefontsize cec unit font valignbottom stylebackground cceeff nowrap alignleft valignbottom div styletextindent marginleft font stylefontsize ptmspoon font div nbsp alignleft valignbottom font stylefontsize cec unit font valignbottom nowrap alignleft valignbottom div styletextindent marginleft font stylefontsize ptmrdormer font div nbsp tdtd alignleft valignbottom font stylefontsize cec unit font valignbottom stylebackground cceeff nowrap alignleft valignbottom div styletextindent marginleft font stylefontsize ptdrpeterson font div nbsp alignleft valignbottom font stylefontsize cec unit font table div alignleft stylemarginleft marginright textindent fontsize fontfamily time new roman time color background ffffff div div stylemargintop fontsize ptnbspdiv div alignleft stylemarginleft marginright fontsize fontfamily arial helvetica color background ffffff bfont stylefontfamily time new roman timescompensation arrangement nonemployee directorsfontb div div stylemargintop fontsize ptnbspdiv div alignleft stylemarginleft marginright textindent fontsize fontfamily time new roman time color background ffffff nonemployee director receive annual fee service director addition director receive service committee board directors chairperson committee presiding director pay annual fee div div stylemargintop fontsize ptnbspdiv div alignleft stylemarginleft marginright textindent fontsize fontfamily time new roman time color background ffffff longterm incentive plan nonemployee director receive nonretainer equity compensation year form restrict defer stock value nonemployee director receive grant share restrict stock base fair market value common stock company february service board mrcharle prince elect board date director receive onetime grant share company common stock member board director div aligncenter stylefontsize fontfamily time new roman time color background ffffff div end logical body html text document document typeex sequence filenameyexvhtm descriptionex statement computation ratio earning fix charge text html head titleextitlehead body bgcolorffffff pagebreak alignleft stylebreakbeforealwaysnbsphp alignright bfont sizeexhibitnbspfontb aligncenter bfont sizejohnson johnson subsidiariesfontb aligncenter bfont sizestatement computation ratio earning fix chargessupsupfontb div aligncenter bfont sizedollar millionsfontb div center table width aligncenter cellspace cellpadde border widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd colspantd tdtd colspantd colspantd tdtd colspan aligncenter nowrapbfont sizefiscal year endedfontbtd colspantd tdtd colspan aligncenter nowraphr size noshadetd colspantd tdtd colspan aligncenter nowrapbfont sizejanuarynbspfontbtd tdtd colspan aligncenter nowrapbfont sizejanuary fontbtd tdtd colspan aligncenter nowrapbfont sizedecembernbspfontbtd tdtd colspan aligncenter nowrapbfont sizedecember fontbtd tdtd colspan aligncenter nowrapbfont sizedecember fontbtd trtr colspantd tdtd colspan aligncenter nowrapbfont sizefontbtd tdtd colspan aligncenter nowrapbfont sizefontbtd tdtd colspan aligncenter nowrapbfont sizefontbtd tdtd colspan aligncenter nowrapbfont sizefontbtd tdtd colspan aligncenter nowrapbfont sizefontbtd colspantd tdtd colspan aligncenter nowraphr size noshadetd tdtd colspan aligncenter nowraphr size noshadetd tdtd colspan aligncenter nowraphr size noshadetd tdtd colspan aligncenter nowraphr size noshadetd tdtd colspan aligncenter nowraphr size noshadetd valignbottom bgcoloreeeeee colspan alignleft valigntop div stylemarginleft textindent font sizedetermination earning fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd colspan alignleft valigntop div stylemarginleft textindent font sizeearning provision taxis income fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizefonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttdtd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd colspan alignleft valigntop div stylemarginleft textindent font sizefixe charge fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd colspanfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizetotal earning define fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizefonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttdtdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd colspanfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd valignbottom bgcoloreeeeee colspan alignleft valigntop div stylemarginleft textindent font sizefixe charge fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd colspan alignleft valigntop div stylemarginleft textindent font sizerent fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttdtd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd colspan alignleft valigntop div stylemarginleft textindent font sizeinter expense capitalization interest fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd colspanfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizetotal fix charge fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizefonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttdtdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd colspanfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd valignbottom bgcoloreeeeee colspan alignleft valigntop div stylemarginleft textindent font sizeratio earning fix charge fontdiv tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignright valignbottomfont sizenbspfonttd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd colspanfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetdtdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignlefthr size noshadetd tdfont sizenbspfonttd table center div alignleft size width alignleft colorblack noshade div table width border cellpadding cellspace widthtd widthtd valigntop tdsupfont sizefontsupfont sizenbspfonttd alignleft font sizethe ratio earning fix charge compute divide sum earning provision taxis income fix charge fix charge fix charge represent interest expense interest capitalize amortization debt discount appropriate interest factor operating lease fonttd table body html text document document typeex sequence filenameyexvtxt descriptionex page annual report shareholder text exhibit management discussion analysis result operation financial condition organization business segment description company business segment company subsidiary approximately employee worldwide engage manufacture sale broad range product health care field company conduct business virtually country world primary focus product relate human health wellbee company organize business segment consumer pharmaceutical medical device diagnostic consumer segment manufacture market broad range product baby child care skin care oral wound care woman health care field nutritional overthecounter pharmaceutical product product market principally general public sell wholesaler directly independent chain retail outlet world pharmaceutical segment include product follow therapeutic area antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology area product distribute directly retailer wholesaler health care professional prescription use general public medical device diagnostic segment include broad range product principally professional field physician nurse therapist hospital diagnostic laboratory clinic product include cordis circulatory disease management product depuy orthopaedic joint reconstruction spinal care product ethicon wound care woman health product ethicon endosurgery minimally invasive surgical product lifescan blood glucose monitoring product orthoclinical diagnostic professional diagnostic product vision care disposable contact lense company structure base principle decentralizedmanagement executive committee johnson johnson principal management group responsible operation allocation resource company committee oversee coordinate activitie consumer pharmaceutical medical device diagnostic business segment subsidiary business segment exception manage citizen country locate product line company compete company large small locate world competition strong product line regard number size compete company involve competition research involve development improvement new exist product process particularly significant development new improve product important company success area business include protect company portfolio intellectual property competitive environment require substantial investment continue research multiple sale force addition development maintenance customer acceptance company consumer product involve significant expenditure advertising promotion management objective company objective achieve superior level capital efficient profitable growth accomplish company management operate business consistent certain strategic principle prove successful time end company participate growth area human health care commit attain leadership position growth segment development innovative product service new product introduce past year account sale billion sale invest research development increase billion significant increase reflect management commitment importance ongoing development new differentiate product service sustain long term growth operating company locate country company view principle decentralize management asset fundamental success broadly base business foster entrepreneurial spirit combine extensive resource large organization ability react quickly local market change challenge company commit develop global business leader drive growth objective business manage long term order sustain leadership position achieve growth provide endure source value shareholder unify management team company dedicated employee achieve objective johnson johnson credo credo provide common set value serve constant reminder company responsibility customer employee communitie shareholder company believe basic principle overall mission improve quality life people enable johnson johnson continue leader health care industry result operation analysis consolidate sale worldwide sale increase billion compare increase sale increase consist follow table caption sale increase volume price currency total table sale company billion billion billion represents increase sale international company billion billion billion represents increase johnson johnson annual report fiveyear compound annual growth rate worldwide international sale respectively tenyear compound annual growth rate worldwide international sale respectively international geographic region experience sale growth consist europe western hemisphere exclude asiapacific africa region sale gain include positive impact currency fluctuation dollar foreign currency europe western hemisphere exclude asiapacific africa region company customer represent total revenue sale cardinal distribution mckesson hboc account total revenue sale mckesson hboc account total revenue result benefit inclusion week note annual closing date detail company estimate fiscal fourth quarter growth rate enhance approximately year approximately net earning impact additional week negligible analysis sale business segment consumer segment consumer segment sale billion increase operational growth account total growth positive currency fluctuation consumer segment sale billion increase international sale billion increase result operation currency fluctuation consumer segment sale growth attributable strong sale performance major franchise include overthecounter otc pharmaceutical nutritional product skin care woman health baby kid care otc franchise sale billion increase overall growth franchise primarily result rapid growth splendar calorie sweetener tabletop category adult pediatric analgesic sale growth partially offset negative impact retail restriction implement product contain pseudoephedrine continue negatively impact business product contain pseudoephedrine reformulate skin care franchise sale billion represent increase attributable sale growth rocr aveenor clean clearr neutrogenar brand product woman health franchise grow billion strong contribution kyr stayfreer product line baby kid care franchise grow billion growth franchise lead success softwashr softlotiontm product line babycentercomr table caption major consumer franchise sale change million dollar otc pharmaceutical nutritional skin care woman health baby kid care total table management discussion analysis result operation financial condition consumer segment sale billion increase operational growth account total growth positive currency impact sale increase international sale increase operational gain positive currency impact consumer segment sale billion increase increase operational growth positive currency impact sale increase international sale gain operational gain positive currency impact pharmaceutical segment pharmaceutical segment sale billion increase change operational growth remain increase relate positive impact currency pharmaceutical segment sale decrease international pharmaceutical segment sale increase include operational growth relate positive impact currency pharmaceutical segment sale include benefit adjustment relate previously estimate performance base rebate allowance manage care contract adjustment sale sale growth segment lead strong performance risperdalr risperidone remicader infliximab topamaxr topiramate levaquinr levofloxacin growth offset generic competition relate duragesicr fentanyl transdermal system ultracetr tramadol hydrochlorideacetaminophen sporanoxr itraconazole hormonal contraceptive key driver growth segment continue success risperdalr risperidone risperdalr constar risperidone long act injection medication treat symptom schizophrenia product achieve billion sale increase prior year ongoing country approval use risperdalr additional indication key factor product growth procritr epoetin alfa eprexr epoetin alfa performance continue adversely affect competition combine product sale billion decline compare volume associate share loss competitive product primary driver decline remicader infliximab biologic approve treatment crohn disease ankylose spondylitis use treatment rheumatoid psoriatic arthritis experience sale billion strong growth prior year fda grant approval remicader treatment psoriatic arthritis fiscal second quarter remicader receive approval treatment ulcerative colitis fda fiscal quarter european commission fiscal quarter additionally european commission grant approval use treatment severe plaque psoriasis fiscal fourth quarter approval contribute strong growth remicader sale topamaxr topiramate approve adjunctive use epilepsy prophylactic treatment migraine account billion sale achieve strong growth prior year june topamaxr approve fda use initial monotherapy treatment epilepsy duragesicr fentanyl transdermal system sale decline billion reduction primarily drive negative impact generic competition begin january additionally generic version duragesicr launch europe authorize generic version duragesicr market company launch fiscal quarter levaquinr levofloxacin floxinr ofloxacin achieve combined sale billion represent growth prior year benefit strong market growth fiscal quarter levaquinr obtain fda approval short course treatment acute bacterial sinusitis hormonal contraceptive franchise account billion sale decline prior year reduce sale ortho tricyclenr norgestimateethinyl estradiol result generic competition partially offset strong growth ortho tricyclenr norgestimateethinyl estradiol low dose oral contraceptive overall sale increase compare ortho evrar norelgestrominethinyl estradiol contraceptive patch approve fda labeling change negative medium coverage concern product safety expect impact sale table caption major pharmaceutical product revenue change million dollar risperdalr risperidonerisperdalr constar risperidone procritreprexr epoetin alfa remicader infliximab topamaxr topiramate duragesicr fentanyl transdermal systemfentanyl transdermal levaquinrfloxinr levofloxacinofloxacin aciphexrparietr rabeprazole sodium hormonal contraceptive total table johnson johnson annual report concertar methylphenidate hcl product treatment attention deficit hyperactivity disorder achieve sale billion represent increase present fda approve generic version substitutable concertar abbreviate new drug application anda generic version concertar pende approve time recent negative publicity fda activity concern attention deficit hyperactivity product impact concertar sales natrecorr nesiritide product treatment patient acutely decompensate congestive heart failure dyspnea rest minimal activity experience significant decline demand recent negative medium coverage meta analysis select historical clinical trial company believe new datum support conclusion medical consumer publication currently approve label natrecorr reflect available datum date response company assemble expert panel review available data clinical development plan product engage dialogue fda panel fda support continue appropriate use natrecorr natrecorr scios inc product purchase company result record intangible asset amortize year remain unamortized intangible value associate natrecorr billion end fiscal fourth quarter base current estimate project future cash flow adjustment intangible asset require pharmaceutical segment sale include benefit adjustment relate previously estimate performancebase rebate allowance manage care contract adjustment base review actual performance level achieve customer compare expect performance level favorable adjustment amount percentage point pharmaceutical segment operational growth vast majority impact adjustment hormonal contraceptive franchise pharmaceutical segment sale billion increase change operational growth remain increase relate positive impact currency pharmaceutical segment sale increase international pharmaceutical segment sale increase include growth operationally relate positive impact currency pharmaceutical segment sale billion increase operational growth positive currency fluctuation sale increase international sale grew include operational growth positive impact currency medical device diagnostic segment medical device diagnostic segment achieve sale billion represent increase prior year operational growth positive impact currency sale increase international sale increase operation currency strong sale growth medical device diagnostic segment achieve multiple franchise cordis franchise key contributor segment result report sale billion increase prior year primary growth driver cordis franchise cypherr sirolimuselute stent international market excellent growth japan biosense webster contribute success cordis franchise continue solid doubledigit growth fiscal fourth quarter biosense webster receive approval use celsiustm rmt diagnostic ablation steerable tip catheterin april july cordis cardiology division cordis corporation receive warning letter fda good manufacturing practice regulation good clinical practice regulation observation follow postapproval site inspection complete early include site involve production cypherr sirolimuselute stent response warn letter cordis improvement quality system anticipate followup site inspection fiscal second quarter table caption major medical device diagnostic franchise sale change million dollar cordisr depuyr ethiconr ethicon endosurgeryr lifescanr vision care orthoclinical diagnosticsr total table management discussion analysis result operation financial condition depuy franchise report billion sale represent growth prior year doubledigit growth depuy orthopaedic joint reconstruction unit lead increase franchise strong sale growth achieve depuy spine unit mitek sport medicine product ethicon worldwide franchise achieve billion sale represent growth prior year contribute strong result continue growth suture mesh product include vicrylr polyglactin plus antibacterial coat suture multipassr needles proceedr tissue separate mesh ethicon endosurgery franchise report billion sale represent growth prior year growth mainly drive endocutter sale include product perform bariatric procedure treatment obesity important focus area franchise doubledigit sale increase advanced sterilization product line key contributor overall sale growth franchise lifescan franchise report billion sale growth rate prior year onetouchr ultrar product line achieve strong growth vision care franchise achieve billion sale growth rate prior year lead continued success acuvuer advancetm brand contact lense hydracleartm day acuvuer additional contributor acuvuer oasystm hydracleartm tired dry eye launch fiscal quarter orthoclinical diagnostic franchise report billion sale represent growth prior year growth mainly drive continued market penetration automate blood type product ongoing growth eci product line success vitrosr clinical chemistry system medical device diagnostic segment achieve sale billion represent increase prior year operational growth positive impact currency sale increase international sale increase operation currency medical device diagnostic segment achieve sale billion represent increase prior year operational growth positive impact currency sale increase international sale increase operation currency analysis consolidate earning provision taxis income consolidated earning provision taxis income increase billion billion earn increase billion percent sale consolidated earning provision taxis income represent decrease improvement decline section thatfollow highlight significant component change consolidated earning provision taxis income cost product sell sell marketing administrative expense cost product sell sell marketing administrative expense percent sale follow table caption sale cost product sell percent increasedecrease prior year sell marketing administrative expense percent increasedecrease prior year table decrease percent sale cost product sell low manufacturing cost primarily relate cypherr sirolimuselute stent ongoing cost containment activity organization partially offset negative impact pharmaceutical product mix decrease percent sale sell marketing administrative expense cost containment initiative pharmaceutical segment partially offset increase investment spend medical device diagnostic segment decrease percent sale cost product sell favorable mix cost improvement initiative decrease percent sale sell marketing administrative expense company focus manage expense partially offset increase investment spending number business focus drive future growth change percent sale sell marketing administrative expense increase percent sale cost product sell change mix product vary cost structure cost retirement enhancement program million expense fiscal fourth quarter research development research activity represent significant company business expenditure relate development new product improvement exist product technical support product compliance governmental regulation protection consumer patient worldwide cost research activity exclude process research development charge follow table caption million dollar research expense percent increase prior year percent sale table research development expense percent sale pharmaceutical segment combine consumer medical device diagnostic segment average respectively johnson johnson annual report research activity accelerate pharmaceutical segment increase billion compound annual growth rate approximately fiveyear period increase investment research development segment demonstrate company focus knowledge base product reflect significant number project late stage development inprocess research development company record inprocess research development iprd charge million tax relate acquisition transform pharmaceuticals inc closure medical corporation peninsula pharmaceuticals inc international commercial right certain patent knowhow field sedation analgesiafrom scott lab inc transform pharmaceuticals inc company specialize discovery superior formulation novel crystalline form drug molecule account million tax iprd charge include operate profit pharmaceutical segment closure medical corporation company expertise intellectual property biosurgical market account million tax iprd charge include operate profit medical device diagnostic segment peninsula pharmaceuticals inc biopharmaceutical company focus develop commercialize antibiotic treat lifethreatening infection account million tax iprd charge include operate profit pharmaceutical segment million tax iprd charge relate scott lab inc refer include operate profit medical device diagnostic segment company record iprd charge million tax result acquisition commercial right certain patent knowhow field sedation analgesia scott lab inc charge include operate profit medical device diagnostic segment company record iprd charge million tax relate acquisition scios inc link spine group inc certain assets orquest inc dimensional pharmaceuticals inc scios inc biopharmaceutical company market product cardiovascular disease research project focus autoimmune disease acquisition scios inc account million tax iprd charge include operate profit pharmaceutical segment link spine group inc acquire provide company exclusive worldwide right charitetm artificial disc treatment spine disorder acquisition link spine group inc account million tax iprd charge include operate profit medical device diagnostic segment orquest inc biotechnology company focus develop biologicallybase implant orthopaedic spine surgery acquisition certain asset orquest inc account million tax iprd charge include operate profit medical device diagnostic segment dimensional pharmaceuticals inc company technology platform focus discovery development potential new drug early stage development inflammation acquisition dimensional pharmaceuticals inc account million tax iprd charge include operate profit pharmaceutical segment income expense net income expense include gain loss relate sale writedown certain investment equity security hold johnson johnson development corporation gain loss disposal property plant equipment currency gain loss minority interest litigation settlement income expense royalty income change net income expense increase income million income balance million include royalty income partially offset expense item individually significant expense balance million include expense item individually significant partially offset royalty income income million include favorable rule stent patent settlement million receive fourth quarter include medical device diagnostic segment operating profit include medical device diagnostic segment operating profit gain sale product line long compatible segment strategic goal income include recovery million loan previously write include pharmaceutical segment operating profit operate profit segment operating profit segment business follow table caption percent segment sale million dollar consumer pharmaceutical med devices diag segment total expense allocate segment earning provision taxis income table amount allocate segment include interest incomeexpense minority interest general corporate incomeexpense management discussion analysis result operation financial condition consumer segment consumer segment operating profit increase prior year percent sale increase slightly despite increase investment spending advertising research development consumer segment operating profit increase prior year percent sale experience decrease primarily additional investment consumer promotion advertising overthecounter pharmaceutical nutritional franchise pharmaceutical segment pharmaceutical segment operating profit decrease percent sale decline change primarily increase investment research development spending impact million iprd expense pharmaceutical segment operating profit increase reflect operate profit percent sale improvement change primarily impact million iprd expense medical device diagnostic segment medical device diagnostic segment operating profit increase percent sale increase increase drive improve gross margin cost reduction program product mix primarily relate cypherr sirolimuselute stent partially offset increase investment research development spend medical device diagnostic segment operating profit increase increase prior year achieve improve gross margin result cost reduction program product mix impact million iprd expense relate acquisition interest income expense interest income increase million primarily high rate interest high average cash balance cash balance include current marketable security billion end average billion compare billion average cash balance interest expense decrease compare decrease average debt balance billion billion interest income increase million primarily high cash balance cash marketable security combine balance end billion average billion significantly high billion average cash balance interest expense decrease million compare primarily decrease average debt balance billion billion provision taxis income worldwide effective income tax rate decrease tax rate attributable tax benefit million record relate technical correction associate american jobs creation act contribute decrease tax rate increase taxable income low tax jurisdiction relative taxable income high tax jurisdiction result increase expenditure high tax jurisdiction shift sale mix benefit partially offset nondeductible iprd charge increase effective tax rate primarily million tax cost intend repatriation undistribute international earning associate american jobs creation act add effective income tax rate liquidity capital resource cash flow cash generate operation select borrowing provide major source fund growth business include work capital capital expenditure acquisition use cash include share repurchase dividend debt repayment cash flow operation billion increase billion increase cash generate operation result net income increase billion net noncash impact iprd charge billion decrease current noncurrent asset alsocontribute increase partially offset billion decrease account payable accrue liability additionally cash payment approximately billion previously accrue taxis repatriation undistribute international earning accordance american job creation act increase approximately billion pension funding compare net cash investing activity decrease billion billion net increase sale investment partially offset billion increase capital expenditure billion increase acquisition activity detail discussion merger acquisition note net cash financing activity decrease billion net issuance debt partially offset increase dividend increase level common stock repurchase cash current marketable security billion end compare billion end cash generate operation amount billion billion cash generate operation billion major factor contribute increase net income increase billion net noncash impact iprd charge johnson johnson annual report finance market risk company use financial instrument manage impact foreign exchange rate change cash flow accordingly company enter forward foreign exchange contract protect value exist foreign currency asset liability hedge future foreign currency product cost gain loss contract offset gain loss underlie transaction appreciation dollar january market rate increase unrealized value company forward contract million conversely depreciation dollar january market rate decrease unrealized value company forward contract million scenario gain loss forward contract offset change value forecast transaction impact future earning cash flow company hedge exposure fluctuation currency exchange rate effect certain asset liability foreign currency enter currency swap contract change spread foreign interest rate company interest rate sensitive financial instrument increase decrease unrealized value company swap contract approximately million scenario maturity gain loss swap contract offset gain loss underlie transaction impact future earning cash flow company use financial instrument trade speculative purpose company policy enter contract party equivalent credit rating counterpartie contract major financial institution significant concentration exposure counterparty management believe risk loss remote total unused credit available company approximate billion include billion credit commitment billion expire september billion expire september include billion uncommitted line bank worldwide expire total borrowing end billion billion respectively net cash cash current marketable security net debt billion compare net cash billion total debt represent total capital shareholder equity total debt total capital shareholder equity share end compare yearend increase august scios inc exercise right redeem outstanding million original principal convertible subordinated note redemption price principal principal debenture accrue interest exclude date redemption period end january material cash commitment johnson johnson continue industrial company triple credit rating summary borrowing find note longterm contractual obligation commitments company longterm contractual obligation primarily lease debt obligation unfunded retirement plan significant obligation satisfy obligation company use cash operation follow table summarize company contractual obligation aggregate maturity january note forfurther detail table caption longterm unfunded operating debt retirement million dollar lease obligation plan total total table amount include interest expense dividend company increase dividend consecutive year cash dividend pay share compare dividend share share dividend distribute follow table caption quarter second quarter quarter fourth quarter total table january board director declare regular cash dividend share payable march shareholders record february company expect continue practice pay regular cash dividend management discussion analysis result operation financial condition information critical accounting policy estimate management discussion analysis result operation financial condition base company consolidated financial statement prepare accordance accounting principle generally accept preparation financial statement require management estimate assumption affect amount report revenue expense asset liability relate disclosure actual result differ estimate company believe understand certain key accounting policy estimate essential achieve insight company operating result financial condition key accounting policy include revenue recognition income taxis legal self insurance contingency valuation longlive asset assumption determine amount record pension employee benefit plan account stock option revenue recognition company recognize revenue product sale good ship deliver title risk loss pass customer provision certain rebate sale incentive trade promotion coupon product return discount customer account reduction sale period relate sale record product discount grant base term arrangement direct indirect market participant market condition include price charge competitor rebate large medicaid rebate provision estimate base sale term historical experience trend analysis project market condition market serve company evaluate market condition product group product primarily analysis wholesaler party sellthrough market research datum internally generate information sale return generally estimate record basedon historical sale return information product exhibit unusual sale return pattern date competition marketing matter specifically investigate analyze accounting sale return accrual company earn service revenue copromotion certain product year present service revenue total revenue include sale customer income taxis income taxis record base amount refundable payable current year include result difference gaap account tax reporting record defer tax asset liability company estimate defer tax asset liability base current tax regulation rate change tax law rate affect record defer tax asset liability future management believe change estimate result material effect company result operation cash flow financial position company repatriate previously disclose billion undistributed international earning accordance american job creation act ajca record tax charge million fiscal fourth quarter fiscal second quarter company record tax benefit million reversal tax liability previously record fiscal fourth quarter associate technical correction ajca january january cumulative undistribute international earning approximately billion billion respectively company intend continue reinv undistributed international earning expand international operation tax expense record cover undistribute portion intend repatriation legal self insurance contingency company record accrual contingency include legal proceeding product liability case arise normal course business accrual base management judgment probability loss opinion legal counsel applicable actuarially determined estimate additionally company record insurance receivable amount party insurer recovery probable appropriate reserve receivables record estimate amount collect party insurer longlive intangible asset company assess change economic condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset assumption estimate change time necessary company record impairment charge fiscal year certain tangible intangible asset write fair value result charge record cost product sell insignificant employee benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide plan base assumption discount rate expect return plan asset expect salary increase health care cost trend rate note detail rate effect rate change company result operation johnson johnson annual report stock option company elect use accounting principle board opinion accounting stock issue employee apb require compensation cost relate stock option charge net income option grant stock option plan exercise price equal market value underlie common stock grant date statement financial accounting standard sfas accounting stockbase compensationtransition disclosurean amendment fasb statement require pro forma disclosure net income earning share determine fair value method accounting stock option apply measure compensation cost note information stock option new accounting standard december fasb issue sfas share base payment statement establish standard accounting transaction entity exchange equity instrument good service focus primarily accounting transaction entity obtain employee service sharebase payment transaction employee stock option restrict stock unit statement require measurement cost employee service receive exchange award equity instrument employee stock option restrict stock unit fair value grant date cost recognize period employee isrequire provide service exchange award requisite service period april sec approve new rule delay effective date sfas annual interim period begin june result company adopt statement fiscal quarter adoption standard company currently intend apply modify retrospective transition method previously report financial statement restate reflect sfas disclosure amount require sfas accounting stock base compensationtransition disclosurean amendment fasb statement company disclose net income earning share effect company apply fair value recognition provision sfas disclosure impact compensation expense net tax million million earning share respectively company implement sfas inventory cost amendment arb fiscal quarter company believe adoption statement material effect result operation cash flow financial position company implement fin accounting conditional asset retirement obligationsan interpretation fasb statement fiscal fourth quarter implementation standard material effect company result operation cash flow financial position company implement sfas exchange nonmonetary assets amendment apb fiscal quarter material effect result operation cash flow financial position follow accounting pronouncement effective material impact company result operation cash flow financial position eitf issue investor apply equity method accounting investment common stock eitf issue accounting preexisting relationship party business combination follow accounting pronouncement effective material impact company result operation cash flow financial position fsp fas accounting disclosure requirement relate medicare prescription drug improvement modernization act sfas amendment statement derivative instrument hedge activity fin fin consolidation variable interest entity interpretation arb economic market factor johnson johnson aware product environment decade policymaker consumer business express concern rise cost health care response concern johnson johnson long stand policy pricing product responsibly period weight average compound annual growth rate johnson johnson net price increase health care product prescription overthecounter drug hospital professional product consumer price index cpi inflation rate moderate part world continue effect worldwide economy consequently way company operate face increase cost company strive maintain profit margin cost reduction program productivity improvement periodic price increase company face worldwide health care change result pricing pressure include health care cost containment government legislation relate sale promotion reimbursement management discussion analysis result operation financial condition company operate environment increasingly hostile intellectual property right generic drug firm file abbreviate new drug application seek market generic form company key pharmaceutical product prior expiration applicable patent cover product event company successful defend patent claim challenge abbreviate new drug application filing generic firm introduce generic version product issue result potential substantial market share revenue loss product information discussion litigation filer abbreviate new drug application note legal proceeding company involve numerous product liability case concern adverse reaction drug medical device damagesclaime substantial company confident adequacy warning instruction use accompany product feasible predict ultimate outcome litigation company believe liability result case substantially cover exist amount accrue company balance sheet available thirdparty product liability insurance company involve number patent trademark lawsuit incidental business ultimate legal financial liability company respect claim lawsuit proceeding refer estimate certainty company opinion base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company balance sheet expect material adverse effect company financial position resolution report period matter significant impact company result operation cash flow period note information legal proceeding common stock market price company common stock list new york stock exchange symbol jnj composite market price range johnson johnson common stock table caption high low high low quarter second quarter quarter fourth quarter yearend close table cautionary factor affect future result annual report contain forwardlooke statement forwardlooke statement relate strictly historical current fact anticipate result base management plan subject uncertainty forwardlooke statement identify use word like plan expect anticipate estimate word similar meaning conjunction thing discussion future operation financial performance company strategy growth product development regulatory approval market position expenditure forwardlooke statement base current expectation future event company guarantee forwardlooke statement accurate company believe reasonable expectation assumption investor realize underlying assumption prove inaccurate unknown risk uncertainty materialize actual result vary materially company expectation projection investor caution place undue reliance forwardlooke statement company assume obligation update forwardlooke statement result new information future event development risk uncertainty include general industry condition competition economic condition interest rate currency exchange rate fluctuation technological advance new product patent attain competitor challenge inherent new product development include obtain regulatory approval challenge patent foreign health care reform governmental law regulation trend health care cost containment increase scrutiny health care industry government agency product efficacy safety concern result product recall regulatory action company report year end january include exhibit discussion additional factor cause actual result differ expectation company note factor permit private security litigation reform act johnson johnson annual report table caption consolidate balance sheet johnson johnson subsidiariesat january january dollar million share share datum note asset current asset cash cash equivalent note marketable security note account receivable trade allowance doubtful account inventory note defer taxis income note prepay expense receivables total current asset marketable security noncurrent note property plant equipment net note intangible asset net note goodwill net note defer taxis income note asset note total asset liabilitie shareholder equity current liability loan note payable note account payable accrue liability accrue rebate return promotions accrue salary wages commission accrue taxis income total current liability longterm debt note defer taxis income note employee relate obligation note liability total liability shareholder equity prefer stockwithout par value authorize unissued share common stockpar value share note authorize share issue share note receivable employee stock ownership plan note accumulate comprehensive income note retain earning common stock hold treasury cost note share share total shareholder equity total liability shareholder equity table note consolidated financial statement consolidate financial statement table caption consolidate statement earning johnson johnson subsidiarie dollar million share figure note sale customer cost product sell gross profit selling marketing administrative expense research expense purchase inprocess research development note interest income interest expense net portion capitalize note income expense net earning provision taxis income provision taxis income note net earning basic net earning share note dilute net earning share note table note consolidated financial statement johnson johnson annual report table caption consolidate statement equity johnson johnson subsidiary note receivable employee accumulate common stock stock treasury comprehensive retain ownership comprehensive issue stock dollar million note total income earning plan esop income balance december net earning cash dividend pay employee stock compensation stock option plan conversion subordinate debenture repurchase common stock business combination comprehensive income net tax currency translation adjustment unrealize gain security pension liability adjustment loss derivative hedge reclassification adjustment total comprehensive income note receivable esop balance december net earning cash dividend pay employee stock compensation stock option plan conversion subordinate debenture repurchase common stock comprehensive income net tax currency translation adjustment unrealize gain security pension liability adjustment gain derivative hedge reclassification adjustment total comprehensive income note receivable esop balance january net earning cash dividend pay employee stock compensation stock option plan conversion subordinate debenture repurchase common stock comprehensive income net tax currency translation adjustment unrealize loss security pension liability adjustment gain derivative hedge reclassification adjustment total comprehensive income note receivable esop balance january table note consolidated financial statement consolidate financial statement table caption consolidate statement cash flow johnson johnson subsidiaries dollar million note cash flow operating activity net earning adjustment reconcile net earning cash flow depreciation amortization property intangible purchase inprocess research development defer tax provision account receivable allowance change asset liability net effect acquisition increase account receivable increasedecrease inventory decreaseincrease account payable accrue liability decreaseincrease current noncurrent asset increase current noncurrent liability net cash flow operating activity cash flow invest activity addition property plant equipment proceed disposal asset acquisition net cash acquire note purchase investment sale investment primarily intangible net cash investing activity cash flow financing activity dividend shareholder repurchase common stock proceed shortterm debt retirement shortterm debt proceed longterm debt retirement longterm debt proceed exercise stock option net cash financing activity effect exchange rate change cash cash equivalent increase cash cash equivalent cash cash equivalent begin year note cash cash equivalent end year note supplemental cash flow datum cash pay year interest income taxis supplemental schedule noncash investing financing activity treasury stock issue employee compensation stock option plan net cash proceed conversion debt acquisition fair value asset acquire fair value liability assume net cash pay acquisition table note consolidated financial statement johnson johnson annual report note consolidated financial statement summary significant accounting policy principle consolidation consolidated financial statement include account johnson johnson subsidiaries intercompany account transaction eliminate description company business segment company subsidiary approximately employee worldwide engage manufacture sale broad range product health care field company conduct business virtually country world primary focus product relate human health wellbee company organize business segment consumer pharmaceutical medical device diagnostic consumer segment manufacture market broad range product baby child care skin care oral wound care woman health care field nutritional overthecounter pharmaceutical product product market principally general public sell wholesaler directly independent chain retail outlet world pharmaceutical segment include product follow therapeutic area antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology area product distribute directly retailer wholesaler health care professional prescription use general public medical device diagnostic segment include broad range product principally professional field physician nurse therapist hospital diagnostic laboratory clinic product include cordis circulatory disease management product depuy orthopaedic joint reconstruction spinal care product ethicon wound care woman health product ethicon endosurgery minimally invasive surgical product lifescan blood glucose monitoring product orthoclinical diagnostic professional diagnostic product vision care disposable contact lense new accounting pronouncement december fasb issue sfas share base payment statement establish standard accounting transaction entity exchange equity instrument good service focus primarily accounting transaction entity obtain employee service sharebase payment transaction employee stock option restrict stock unit statement require measurement cost employee service receive exchange award equity instrument employee stock option restrict stock unit fair value grant date cost recognize period employee require provide service exchange award requisite service period april sec approve new rule delay effective date sfas annual interim period begin june result company adopt statement fiscal quarter adoption standard company currently intend apply modify retrospective transition method previously report financial statement restate reflect sfas disclosure amount require sfas accounting stock base compensationtransition disclosurean amendment fasb statement company disclose net earning earning share effect company apply fair value recognition provision sfas disclosure impact compensation expense net tax million million earning share respectively company implement sfas inventory cost amendment arb fiscal quarter company believe adoption statement material effect result operation cash flow financial position company implement fin accounting conditional asset retirement obligationsan interpretation fasb statement fiscal fourth quarter implementation standard material effect company result operation cash flow financial position company implement sfas exchange nonmonetary assets amendment apb fiscal quarter material effect result operation cash flow financialposition follow accounting pronouncement effective material impact company result operation cash flow financial position eitf issue investor apply equity method accounting investment common stock eitf issue accounting preexisting relationship party business combination follow accounting pronouncement effective material impact company result operation cash flow financial position fsp fas accounting disclosure requirement relate medicare prescription drug improvement modernization act sfas amendment statement derivative instrument hedge activity fin fin consolidation variable interest entitiesan interpretation arb cash equivalent company consider security maturity month purchase cash equivalent investment shortterm marketable security carry cost approximate fair value investment classified availableforsale carry estimate fair value unrealize gain loss record component accumulate comprehensive income longterm debt security company ability intent hold maturity carry amortize cost approximate fair value note consolidated financial statement management determine appropriate classification investment debt equity security time purchase reevaluate determination balance sheet date company periodically review investment equity security impairment adjust investment fair value decline market value deem temporary property plant equipment depreciation property plant equipment state cost company utilize straightline method depreciation estimate useful life asset table caption building building equipment year land leasehold improvement year machinery equipment year table company capitalize certain computer software development cost include machinery equipment incur connection develop obtain computer software internal use capitalize software cost amortize estimate useful life software generally range year company review longlive asset assess recoverability undiscounted cash flow necessary charge impairment longlive asset record present value future cash flow carry value asset revenue recognition company recognize revenue product sale good ship deliver title risk loss pass customer provision certain rebate sale incentive trade promotion coupon product return discount customer account reduction sale period relate sale record product discount grant base term arrangement direct indirect market participant market condition include price charge competitor rebate large medicaid rebate provision estimate base sale term historical experience trend analysis project market condition market serve company evaluate market condition product group product primarily analysis wholesaler party sellthrough market research datum internally generate information sale return generally estimate record base historicalsale return information product exhibit unusual sale return pattern date competition marketing matter specifically investigate analyze accounting sale return accrual company earn service revenue copromotion certain product include sale customer shipping handle shipping handling cost incur million million million respectively include sell marketing administrative expense revenue receive shipping handle sale customer period present inventory inventory state low cost market determine firstin firstout method goodwill intangible asset effective begin fiscal year accordance sfas company discontinue amortization relate exist goodwill indefinite live intangible asset nonamortizable sfas require goodwill nonamortizable intangible asset assess annually impairment company complete annual impairment test fiscal fourth quarter impairment determine future impairment test perform annually fiscal fourth quarter soon trigger event occur intangible asset finite useful life continue amortize useful life review impairment warrant economic condition note detail intangible asset financial instrument company follow provision sfas accounting derivative instrument hedge activity amend sfas account certain derivative instrument certain hedging activity sfas amendment statement derivative instrument hedge activity collectively refer sfas sfas require derivative instrument record balance sheet fair value change fair value derivative record period current earning comprehensive income depend derivative designate hedge transaction type hedge transaction company use forward exchange contract manage exposure variability cash flow primarily relate foreign exchange rate change future intercompany product party purchase raw material denominate foreign currency company use currency swap manage currency risk primarily relate borrowing type derivative designate cash flow hedge additionally company use forward exchange contract offset exposure certain foreign currency asset liabilitie forward exchange contract designate hedge change fair value derivative recognize earning offset current earning effect relate foreign currency asset liability designation cash flow hedge entrance date derivative contract inception derivative expect highly effective change fair value derivative designate cash flow hedge highly effective record accumulate comprehensive income underlie transaction affect earning reclassify earning account hedge transaction fair value derivative instrument forward foreign exchange contract currency swap aggregation currency johnson johnson annual report future cash flow discount present value prevail market interest rate subsequently convert dollar current spot foreign exchange rate ongoing basis company assess derivative continue highly effective offset change cash flow hedge item derivative long expect highly effective hedge accounting discontinue hedge ineffectiveness include current period earning insignificant company document relationship hedge item derivative overall risk management strategy include reason undertake hedge transaction enter derivative objective strategy minimize foreign currency exposure impact company financial performance protect company cash flow adverse movement foreign exchange rate ensure appropriateness offinancial instrument manage enterprise risk associate financial institution product liability accrual product liability claim record undiscounted basis probable liability incur liability reasonably estimate base exist information accrual adjust periodically additional information available result cost availability factor effective november company cease purchase party product liability insurance base availability prior coverage receivables insurance recovery relate product liability claim record undiscounted basis probable recovery realize research development research development expense expense incurred upfront milestone payment party connection research development collaboration expense incur point regulatory approval payment party subsequent regulatory approval capitalize amortize remain useful life relate product amount capitalize payment include intangible net accumulate amortization advertising cost associate advertising expense year incur include sell marketing administrative expense advertising expense worldwide comprise television radio print medium internet advertising billion billion billion income taxis company intend continue reinv undistributed international earning expand international operation tax expense record cover undistribute portion intend repatriation january january cumulative undistribute international earning approximately billion billion respectively defer income taxis recognize tax consequence temporary difference apply enact statutory tax rate applicable future year difference financial reporting tax basis exist asset liability net earning share basic net earning share compute divide net earning available common shareholder weight average number common share outstanding period dilute net earning share reflect potential dilution occur security exercise convert common stock treasury stock method stock option january company stockbase employee compensation plan describe note company account plan recognition measurement principle accounting principle board opinion accounting stock issue employee apb relate interpretation compensation cost record net earning stock option option grant plan exercise price equal market value underlie common stock date grant require sfas accounting stockbase compensationtransition disclosurean amendment fasb statement follow table show estimate effect net income earning share company apply fair value recognition provision sfas accounting stockbase compensation stockbase employee compensation table caption dollar million share datum net earning report compensation expense net earning pro forma net earning share basic report pro forma diluted report pro forma table determine fair value base method awards net tax use estimate preparation consolidate financial statement conformity accounting principle generally accept require management estimate assumption affect amount report estimate accounting sale discount rebate allowance incentive product liability income taxis depreciation amortization employee benefit contingency asset liability valuation instance determine annual pension postemployment benefit cost company estimate rate return plan asset cost future health care benefit actual result differ estimate note consolidated financial statement annual closing date company follow concept fiscal year end sunday nearest end month december normally fiscal year consist week year fiscal year consist week case reclassification certain prior year amount reclassify conform current year presentation inventory end inventory comprise table caption dollar millions raw material supply good process finish good table property plant equipment end property plant equipment cost accumulate depreciation table caption dollar millions land land improvement building build equipment machinery equipment construction progress accumulate depreciation table company capitalize interest expense cost construction offacilitie equipment interest expense capitalize million million million respectively depreciation expense include amortization capitalize interest billion billion billion respectively retirement disposal property plant equipment cost relate accumulate depreciation amortization eliminate asset accumulate depreciation account respectively difference net asset value proceed record earning rental expense lease commitment rental space vehicle manufacture equipment office datum processing equipment operating lease approximately million million million approximate minimum rental payment require operating lease initial remain noncancelable lease term excess year january table caption dollar million total table commitment capital lease significant employee relate obligation end employee relate obligation table caption dollar millions pension benefit postretirement benefit postemployment benefit defer compensation current benefit payable employee relate obligation table prepay employee relate obligation million million respectively include asset consolidate balance sheet borrowing component longterm debt follow table caption effective effective dollar million rate rate zero coupon convertible subordinated debenture debenture debenture note debenture note convertible subordinated note industrial revenue bond current portion table weight average effective rate convertible subordinate note redeem scios inc august johnson johnson annual report company access substantial source fund numerous bank worldwide total unused credit available company approximate billion include billion credit commitment billion expire september billion expire september include billion uncommitted line bank worldwide expire interest charge borrowing credit line agreement base bid provide bank prime rate london interbank offer rate libor plus applicable margin commitment fee agreement material period present company file shelf registration security exchange commission effective january enable company issue billion debt security warrant purchase debt security debt issue shelf remain available january august scios inc exercise right redeem outstanding million original principal convertible subordinated note redemption price principal principal debenture accrue interest exclude date redemption july alza corporation complete private offering zero coupon convertible subordinated debenture issue price principal maturity january outstanding debenture total principal maturity million yield maturity annum compute semiannual bond equivalent basis periodic interest payment term debenture holder entitle convert debenture approximately million share johnson johnson stock price share approximately million share issue january voluntary conversion note holder option holder debenture repurchase company july purchase price equal issue price plus accrete original issue discount purchase date company option elect deliver johnson johnson common stock cash combination stock cash event repurchase debenture company option redeem debenture july issue price plus accrete original issue discount january january fair value base quote market value debenture million million respectively shortterm borrowing current portion long term debt amount million end million relate commercial paper program remainder represent principally local borrowing international subsidiary november company exercise right redeem million aggregate principal debenture redemption price principal principal debenture accrue interest date redemption shortterm borrowing current portion longterm debt amount million end principally local borrowing international subsidiary aggregate maturity longterm obligation commence table caption dollar millions table intangible asset goodwill end gross net amount intangible asset table caption dollar millions trademark nonamortizable gross accumulate amortization trademark nonamortizable net patent trademarksgross accumulate amortization patent trademarksnet intangiblesgross accumulate amortization intangible net subtotal intangible assetsgross accumulate amortization subtotal intangible assetsnet goodwill gross accumulate amortization goodwill net total intangible assetsgross accumulate amortization total intangible assetsnet table goodwill january january allocate segment business follow table caption med dev dollar million consumer pharm diag total goodwill december acquisition translationother goodwill january acquisition translationother goodwill january table note consolidated financial statement weight average amortization period patent trademark intangible asset year year respectively amortization expense amortizable intangible asset fiscal year end january january december million million million tax respectively certain patent intangible write fair value fiscal year result charge include amortization expense estimate amortization expense succeed year approximate million tax year substantially amortization expense include cost product sell income taxis provision taxis income consist tablecaption dollar million currently payable tax international taxis defer taxis international taxis table comparison income tax expense federal statutory rate company effective tax rate follow table caption dollar millions international earning taxis income tax rate statutory puerto rico ireland operation research tax credit state local international subsidiary exclude ireland repatriation international earning iprd effective tax rate table company subsidiary operate puerto rico tax incentive grant possession tax credit expire apply certain operation puerto rico addition company subsidiary manufacture ireland incentive tax rate second quarter tax benefit million record reversal tax liability relate technical correction associate american jobs creation act decrease tax rate attribute increase taxable income low tax jurisdiction relative taxable income high tax jurisdiction result increase expenditure high tax jurisdiction shift sale mix temporary difference carry forwards follow table caption defer tax defer tax dollar million asset liability asset liability employee relate obligation depreciation nondeductible intangible international capitalize tax reserve liabilitie income report tax purpose miscellaneous international capitalize intangible miscellaneous total deferred income taxis table difference net defer tax income balance sheet net defer tax include taxis income balance sheet johnson johnson annual report international currency translation translation subsidiary operate nonus dollar currency company determine local currency international subsidiary functional currency highly inflationary economy define compound cumulative rate inflation past year substantial portion cash flow local currency consolidate international subsidiary balance sheet currency effect record component accumulate comprehensive income equity account include result translate balance sheet asset liability current exchange rate locate highly inflationary economy reflect operating result analysis change foreign currency translation adjustment include note net currency transaction translation gain loss include income expense loss million million million respectively common stock stock option plan stock compensation agreement january company stockbase compensation plan share outstanding contract company stock option plan long term incentive plan nonemployee director plan biosense centocor innovasive device alza inverness scio stock option plan option grant plan stock option plan long term incentive plan stock option plan expire april option grant subsequent date long term incentive plan stock option expire year date grant vest service period range year option grant current market price date grant long term incentive plan company issue million share common stock share available future grant long term incentive plan million end summary status company stock option plan january january december change year end date present table caption weight option average share thousand outstanding exercise price balance december option grant option exercise option canceledforfeite balance december option grant option exercise option canceledforfeite balance january option grant option exercise option canceledforfeite balance january tablethe average fair value option grant fair value estimate blackschole option pricing model base weighted average assumption table caption riskfree rate volatility expect life yrs yrs yrs dividend yield table follow table summarize stock option outstanding exercisable january table caption share thousand outstanding exercisable average average exercise average exercise exercise price range option life price option price table average contractual life remain year stock option exercisable january december option average price option average price respectively note consolidated financial statement table caption segment business geographic area sale customer dollar million consumerunited states international total pharmaceutical united states international total medical device diagnostic united states international total worldwide total table table caption operating profit identifiable asset dollar million consumer pharmaceutical medical device diagnostic segment total expense allocate segment general corporate worldwide total table table caption addition property depreciation plant equipment amortization dollar millions consumer pharmaceutical medical device diagnostic segment total general corporate worldwide total table table caption sale customer longlive asset dollar million united states europe western hemisphere exclude asiapacific africa segment total general corporate non longlived asset worldwide total table note description segment company operate export sale intersegment sale significant company customer represent total revenue sale distributor account total revenue total revenue amount allocate segment include interest incomeexpense minority interest general corporate incomeexpense general corporate include cash marketable security include million million inprocess research development iprd pharmaceutical medical device diagnostic segment respectively include million iprd medical device diagnostic segment include million iprd pharmaceutical segment million iprd million arbitration ruling stent patent medical device diagnostic segment longlive asset include property plant equipment net respectively intangible asset net respectively johnson johnson annual report table caption accumulate comprehensive income component comprehensive incomeloss consist follow total unrealized gain accumulate foreign gain pension loss currency loss liability derivative comprehensive dollar million translation security adjustment hedge incomeloss dec change net change hedging transaction net reclasse net earning net change dec change net change hedging transaction net reclasse net earning net change jan change net change hedging transaction net reclasse net earning net change jan table total comprehensive income include reclassification adjustment gain million realize sale equity security associate tax expense million total comprehensive income include reclassification adjustment gain million realize sale equity security associate tax expense million total comprehensive income include reclassification adjustment gain million realize sale equity security associate tax expense million tax effect unrealize gainslosses equity security balance expense million million million respectively tax effect relate minimum pension liability million tax effect gainslosse derivative hedge loss million benefit million million respectively note additional information relate derivative hedge currency translation adjustment currently adjust income taxis relate permanent investment international subsidiary pension benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide company provide postretirement benefit primarily health care retire employee dependent international employee cover governmentsponsored program direct cost company significant retirement plan benefit primarily base employee compensation year retirement number year service international subsidiary plan fund deposit trustee annuity purchase group contract reserve provide company fund retiree health care benefit advance right modify plan future company use date consolidate financial statement january january respectively measurement date international retirement benefit plan net periodic benefit cost company define benefit retirement plan benefit plan include follow componentstable caption retirement plan benefit plan dollar million service cost interest cost expect return plan asset amortization prior service cost amortization net transition asset recognize actuarial loss curtailment settlement special termination benefit net periodic benefit cost table note consolidated financial statement net periodic benefit cost attributable retirement plan million million million company offer voluntary retirement program enhance benefit call retirement enhancement program rep eligible regular fulltime employee attain age year pension credit service june program enhancement include elimination early retirement reduction pension benefit purpose normally year prior age special termination benefit week pay year credit service program result onetime increase pension expense million reflect value retirement enhancement weightedaverage assumption follow table represent rate develop actuarial present value project benefit obligation year list net periodic benefit cost follow year table caption retirement plan benefit plan benefit plan discount rate expect longterm rate return plan asset rate increase compensation level international benefit plan discount rate expect longterm rate return plan asset rate increase compensation level table company discount rate determine consider current yield curve represent high quality longterm fix income instrument result discount rate consistent duration plan liability expect longterm rate return plan asset assumption determine building block approach consider historical average real return asset class certain country historical return meaningful consideration give local market expectation longterm return follow table display assume health care cost trend rate individual table caption health care plan health care cost trend rate assume year rate cost trend rate assume decline ultimate trend year rate reach ultimate trend rate table onepercentagepoint change assume health care cost trend rate follow effect table caption onepercentage onepercentage dollar million point increase point decrease health care plan total interest service cost postretirement benefit obligation table johnson johnson annual report follow table set forth information relate benefit obligation fair value plan asset yearend company define benefit retirement plan postretirement plan table caption dollar million retirement plan benefit plan change benefit obligation project benefit obligation begin year service cost interest cost plan participant contribution amendment actuarial loss divestiture acquisition curtailment settlement benefit pay plan effect exchange rate project benefit obligation end year change plan asset plan asset fair value begin year actual return plan asset company contribution plan participant contribution divestiture benefit pay plan asset effect exchange rate plan asset fair valueend year table strategic asset allocation determine country base nature liability consideration demographic composition plan participant average age year service active versus retiree status company plan consider nonmature plan longterm strategic asset allocation consistent type plan emphasis place diversify equity broad basis combine currency match fix income asset follow table display project future benefit payment company retirement benefit plan table caption dollar millions project future benefit payment retirement plan benefit plan gross medicare rebate benefit plan net table company require fund retirement plan order meet minimum statutory funding requirement international plan fund accordance local regulation additional discretionary contribution deem appropriate meet longterm obligation plan certain country fund pension plan common practice funding provide economic benefit consequently company pension plan fund follow table display project future minimum contribution company international unfunded retirement plan amount include discretionary contribution company elect future table caption dollar millions project future contribution unfunded retirement plan unfunde international retirement plan table note consolidated financial statement table caption company retirement plan asset allocation january january target allocation follow percent target plan asset allocation retirement plan equity security debt security total plan asset international retirement plan equity security debt security real estate total plan asset table company benefit plan unfunded life insurance contract asset million million january january respectively fair value johnson johnson common stock directly hold plan asset million total plan asset million total plan asset january january respectively amount recognize company balance sheet consist follow table caption retirement plan benefit plan dollar million cplan assets fair value project benefit obligation fund status unrecognize actuarial loss unrecognize prior service cost unrecognized net transition asset total recognize consolidated balance sheet book accrual prepaid benefit intangible asset accumulate comprehensive income total recognize consolidated balance sheet table accumulate benefit obligation international define benefit retirement plan million million january january respectively minimum pension liability adjustment require actuarial present value accumulate benefit obligation abo exceed fair value plan asset accrue pension liability minimum pension liability intangible asset accumulate comprehensive income million million respectively relate primarily plan outside plan accumulate benefit obligation excess plan asset consist follow table caption retirement plan dollar millions accumulate benefit obligation project benefit obligation plan asset fair value table johnson johnson annual report december medicare prescription drug improvement modernization act enact introduce prescription drug benefit medicare subsidy sponsor retiree health care benefit plans company application center medicare medicaid services attest plan actuarial equivalence medicare accept subsidy reimbursement expect beginning change estimate participation rate capita claim cost result act company recognize effect subsidy prospective basis june recognition reduce beforetax aftertax expense million accumulate postretirement benefit obligation million cash equivalent marketable security table caption january january amortize unrealize estimate amortize unrealized estimate dollar million cost gainslosse fairvalue cost gainslosse fairvalue current investment government security obligation corporate debt security money market fund time deposit collateralize mortgage obligation asset back security bank note total cash equivalent current marketable security noncurrent investment marketable security table current marketable security include billion billion classified cash equivalent balance sheet january january respectively financial instrument company follow provision sfas require derivative instrument record balance sheet fair value january balance defer net gain derivative include accumulate comprehensive income million aftertax additional information note company expect substantially reclassify earning month result transaction expect occur period maximum length time company hedge transaction exposure month ultimately realize earning differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity derivative derivative gainslosse initially report component comprehensive income reclassify earning period forecast transaction affect earning year end january january december net impact hedge ineffectiveness transaction qualify hedge accounting discontinuance hedge company financial statement insignificant refer note disclosure movement accumulate comprehensive income concentration credit risk company invest excess cash deposit major bank world high quality money market instrument company policy make investment commercial institution equivalent credit rating average investment mature month company incur relate loss saving plan company voluntary saving plan design enhance exist retirement program cover eligible employee company match percentage employee contribution consistent provision plan heshe eligible salary plan onethird company match pay company stock employee stock ownership plan esop employee choose note consolidated financial statement redirect investment establish esop company loan million esop trust purchase share company stock open market exchange company receive note balance record reduction shareholder equity remain share hold esop trust allocate participant account end february march go forward company match cash follow individual employee investment election total company contribution plan million million million merger acquisition divestiture certain business acquire million cash million liability assume acquisition account purchase method accordingly result operation include financial statement respective date acquisition acquisition include transform pharmaceuticals inc company specialize discovery superior formulation novel crystalline form drug molecule closure medical corporation company expertise intellectual property biosurgical market peninsula pharmaceuticals inc biopharmaceutical company focus develop commercialize antibiotic treat lifethreatening infection right consumer professionally dispense rembrandtr brand oral care product whiten toothpaste strip system mouth rinse excess purchase price estimate fair value tangible asset acquire amount million assign identifiable intangible asset residual record goodwill approximately million identify value inprocess research development iprd primarily associate acquisition transform pharmaceuticals inc closure medical corporation peninsula pharmaceuticals inc iprd charge relate acquisition transform pharmaceuticals inc million associate research relate discovery application superior formulation value iprd calculate cash flow projection discount risk inherent project discount rate apply iprd charge relate acquisition closure medical corporation million associate omnextm surgical sealant vascular indication outside europe potential indication worldwide value iprd calculate cash flow projection discount risk inherent project probability success factor vascular indication indication reflect inherent clinical regulatory risk discount rate apply vascular indication iprd charge relate acquisition peninsula pharmaceuticals inc million associate development doripenem phase iii clinical trial value iprd calculate cash flow projection discount risk inherent project probability success factor reflect inherent clinical regulatory risk discount rate apply remain million iprd associate acquisition international commercial right certain patent knowhow field sedation analgesia scott lab inc value iprd calculate cash flow projection discount risk inherent project discount rate certain business acquire million cash million liability assume acquisition account purchase method accordingly result operation include financial statement respective date acquisition addition term acquisition agreement link spine group inc million cash pay owner link spine group inc base date food drug administration fda approve charite artificial disc total cash expenditure relate acquisition million acquisition include merck interest johnson johnsonmerck consumer pharmaceutical european nonprescription pharmaceutical joint venture include infrastructure brand asset manage european joint venture egea biosciences inc exercise option acquire remain outstanding stock own johnson johnson develop proprietary technology platform call gene writer allow rapid highly accurate synthesis dna sequence gene assembly construction large synthetic gene library artemis medical inc privately hold company ultrasound xray visible biopsy site breast marker hybrid marker commercial right certain patent knowhow field sedation analgesia scott lab inc biapharm sas privately hold french producer marketer skin care product center lead brand biafiner asset micome privately own manufacturer spinal implant primarily focus supply german market acquisition ambir skin care brand woman color excess purchase price estimate fair value tangible asset acquire amount million assign identifiable intangible asset residual record goodwill million relate fda approval charite artificial disc record additional goodwill associated link spine group inc acquisition total addition intangible goodwill million approximately million identify value iprdassociate scott lab inc acquisition value iprd calculate cash flow projection discount risk inherent project discount rate certain business acquire billion cash million liability assume acquisition account purchase method accordingly result operation include financial statement respective date acquisition acquisition include link spine group inc privately own corporation exclusive worldwide right johnson johnson annual report charitetm artificial disc scios inc biopharmaceutical company market product cardiovascular disease research project focus autoimmune disease dimensional pharmaceuticals inc company technology platform focus discovery development therapeutic small molecules orapharma inc specialty pharmaceutical company focus development commercialization unique oral therapeutic certain asset orquest inc privately hold biotechnology company focus develop biologicallybase implant orthopaedic spine surgery excess purchase price estimate fair value tangible asset acquire amount billion assign identifiable intangible asset residual record goodwill approximately million identify value iprd primarily associate acquisition link spine group inc scios inc iprd charge relate link spine group inc acquisition million associate charitetm artificial disc value iprd calculate cash flow projection discount risk inherent project probability success factor reflect inherent clinical regulatory risk discount rate purchase price link spine group inc acquisition allocate tangible identifiable intangible asset acquire liability assume base estimate fair value acquisition date excess purchase price fair value asset liability acquire approximately million allocate goodwill substantially allocate goodwill deductible tax purpose iprd charge relate scios inc million largely associate kinase inhibitor program value iprd calculate cash flow projection discount risk inherent project probability success factor discount rate purchase price scios inc acquisition allocate tangible identifiable intangible asset acquire liability assume base estimate fair value acquisition date identifiable intangible asset include patent trademark value approximately billion excess purchase price fair value asset liability acquire approximately million allocate goodwill substantially allocate goodwill deductible tax purpose remain iprd associate orquest inc dimensional pharmaceutical inc charge million million respectively supplemental pro forma information sfas business combination sfas goodwill intangible asset provide impact aforementione acquisition material effect company result operation cash flow financial position divestiture material effect company result operation cash flow financial position legal proceeding product liability company involve numerous product liability case unite states concern adverse reaction drug medical device damage claim substantial company confident adequacy warning instruction use accompany product feasible predict ultimate outcome litigation company believe liability result case substantially cover exist amount accrue company balance sheet available thirdparty product liability insurance group case company concern product company subsidiary janssen pharmaceutica inc janssen propulsidr cisapride withdraw general sale restrict limited use wake publicity event numerous lawsuit file janssen company propulsidr state federal court country action seek substantial compensatory punitive damage accuse janssen company inadequately testing warning drug effect promote offlabel use promotion addition janssen company enter tolling agreement plaintiff counsel halting run statute limitation respect potential claim significant number individual whilethose attorney evaluate sue janssen company behalf february janssen announce reach agreement principle plaintiff steer committee psc propulsidr federal multidistrict litigation mdl resolve federal lawsuit relate propulsidr agreement effective death claimant remainder agree term settlement addition individual file lawsuit claim subject tolling agreement suspend run statute limitation claim agree participate settlement effective march confirm psc mdl enrol plaintiff claimants settlement program agreement effective death plaintiff subject program confirm enrol plaintiff subject program confirm enrol addition toll claimant confirm enrol participate settlement submit medical record independent panel physician determine claim injury cause propulsidr meet standard compensation standard meet courtappointe special master determine compensatory damage janssen pay compensation escrow account million establish administrative fund million pay legal fee psc million approve court note consolidated financial statement participate settlement program plaintiff toll claimant plaintiff potentially subject mdl settlement enroll plaintiff file case federal court subsequent february subject mdl settlement state court action subject settlement participate subject mdl settlement plaintiff allege die use drug assert personal injury claim nature claim toll claimant unknown remain federal state plaintiff case venue mississippi december janssen reach agreement mdl psc plaintiff state liaison committee slc create second settlement program resolve remain state federal lawsuit file november remain unfiled claim subject tolling agreement new program effective plaintiff represent decedent plaintiff agree term settlement new program allow enrollment claimant eligible prior settlement program choose enroll plus state court plaintiff federal court plaintiff file february eligible janssen pay compensation minimum million maximum million new settlement program depend percentage enrollment threshold janssen establish administrative fund exceed million pay legal fee exceed million subject court approval janssen company believe adequate selfinsurance accrual thirdparty product liability insurance respect case communication company excess insurance carrier raise certain defense liability policy date decline voluntarily reimburse janssen company propulsidrrelate cost despite demand payment hearing hold london arbitration proceeding commence janssen company allianz underwriter insurance company issue layer applicable excess insurance coverage obtain reimbursement propulsidrrelate cost proceed resolve fashion satisfactory janssen company november company commence arbitration lexington insurance company issue second layer excess insurance coverage opinion company excess carrier remain legally obligate provide coverage propulsidrrelate loss issue affirmative stent patent litigation patent infringement action try delaware federal district court late cordis corporation cordis subsidiary johnson johnson obtain verdict infringement patent validity damage awards boston scientific corporation boston scientific medtronic ave inc medtronic base number cordis vascular stent patent december jury damage action boston scientific return verdict million december jury medtronic action return verdict million sum represent lose profit reasonable royalty damage compensate cordis infringement include pre post judgment interest march district judge grant boston scientific new trial liability damage vacate verdict medtronic onlegal ground august court appeal federal circuit find trial judge err vacate verdict medtronic remand case trial judge proceeding march remain issue try remand case medtronic retrial proceed boston scientific jury return verdict infringement patent validity favor cordis retrial cordis request trial court reinstate interest verdict obtain entity defendant case file posttrial motion seek vacate jury verdict alternatively grant new trial damage cordis pende delaware federal district court second action medtronic ave accuse medtronic infringement sale stent product introduce medtronic subsequent gfxr microstentr product subject early action reference second action stay april pende outcome arbitration hold late concern medtronic claim product issue case license pursuant license january cordis file patent infringement action boston scientific delaware federal district court accuse expresstmtaxusr liberte stent infringe palmaz patent expire november liberte stent accuse infringe cordis gray patent expire june jury find expresstm taxusr liberte stent infringe palmaz patent liberte stent infringe gray patent boston scientific file posttrial motion seek vacate verdict obtain new trial motion deny trial damage willfulness future johnson johnson annual report patent litigation johnson johnson subsidiaries product johnson johnson subsidiary subject patent lawsuit outcome potentially adversely affect ability subsidiary sell product require payment past damage future royalty respect matter johnson johnson subsidiary involve vigorously defend claim infringement dispute appropriate validity enforceability patent claim assert july jury federal district court delaware find cordis cypherr stent infringe boston scientific ding patent cordis cypherr velocityr stent infringe boston scientific corporation jang patent jury find patent valid cordis ask judge overturn jury verdict grant new trial judge overturn jury verdict damage willfulness trial boston scientific seek injunction cypherr uphold trial court cordis appeal jury verdict court appeal federal circuit march boston scientific case assert infringement cypherr stent boston scientific patent schedule trial delaware federal district court case boston scientific seek injunction substantial damage january federal district court southern district florida grant cordis summary judgment dismiss breach contract patent infringement suit file cordis arlaine gina rockey seek royalty sales cordis balloon expandable stent plaintiff file appeal court appeal federal circuit action file belgium boston scientific kastenhofer patent boston scientific seek paneuropean injunction sale infringe catheter injunction effective belgium country serve european patent office trial schedule occur follow chart summarize patent lawsuit concern product johnson johnson subsidiaries table caption plaintiff product company patent patent holder court trial date date file drug eluting stent cordis grainger boston scientific corp del stents cordis boneau medtronic inc del twolayer catheters cordis kastenhofer boston scientific corp cal forman belgium stent cordis israel medinol multiple jurisdiction contact lense vision care nicolson ciba vision fla table trial date establish litigation filer abbreviate new drug application andas follow chart indicate lawsuit pende generic firm file abbreviate new drug application seek market generic form product sell subsidiary company prior expiration applicable patent cover product anda typically include allegation noninfringement invalidity unenforceability patent event subsidiary company involve successful action month stay expire rule district court obtain firm involve ability introduce generic version product issue result substantial market share revenue loss product company subsidiary previously communicate note follow chart month stay schedule expire respect anda challenge ortho tricyclenr risperdalr topamaxr trial occur expiration stay respect ortho tricyclenr unlikely occur respect risperdalr occur case topamaxr month stay extend preliminary injunction grant outcome uncertain final fda approval market occur shortly expiration month stay firm launch anda product trial liable potentially lose profit find trial infringe valid patent typically anda product launch circumstance nonetheless risk launch occur case involve drug johnson johnson subsidiaries risk launch rule note consolidated financial statement table caption brand patentnda generic trial date month product holder challenger court date file stay expire aciphexr delay eisai teva sdny release tablet janssen reddy sdny mylan sdny concertar mcneilppc impax ddel alza andrx control release tablet ditropan xlr orthomcneil mylan dwv controlled release tablet alza impax dcal levaquinr tablet daiichi mylan dwv tablets jjprd orthomcneil teva dnj levaquinr injectable daiichi jjprd sicor teva dnj single use vial orthomcneil mgml premix levaquinr injectable daiichi jjprd american dnj single use vial orthomcneil pharmaceutical partner quixinr ophthalmic daiichi hitech dnj solution levofloxacin orthomcneil pharmacal ophthalmic solution ortho tri cyclenr orthomcneil barr dnj pepcidr complete mcneilppc perrigo sdny razadynetm janssen teva del mylan del reddy del purepac del barr del par del alphapharm del risperdalr tablets janssen mylan dnj reddy dnj tablets risperdalr mtab janssen reddy dnj barr dnj topamaxr orthomcneil mylan dnj tablet cobalt dnj topamaxr sprinkle orthomcneil cobalt dnj capsule ultracetr tram orthomcneil kali par dnj apap tablet teva dnj caraco mich table trial date establish action mylan pharmaceuticals usa mylan involve company subsidiary orthomcneil pharmaceutical inc orthomcneil product ditropan xlr oxybutynin chloride court september find ditropan xlr patent invalid infringe mylan anda product orthomcneil alza corporation alza subsidiary company appeal action impax impax receive judgment invalidity base decision mylan suit orthomcneil alza appeal decision appeal consolidate mylan impax receive final fda approval launch anda product approval come point johnson johnson annual report december mylan announce enter agreement orthomcneil pharmaceutical inc oxybutynin chloride extend release tablet agreement relate orthomcneil supply certain dosage oxybutynin chloride extend release tablet second relate patent license alza intellectual property ditropan xlr term agreement confidential depend outcome appeal west virginia court decision subject review federal trade commission week follow adverse rule ditropan xlr anda litigation mylan september orthomcneil alza receive antitrust class action complaint file indirect purchaser product complaint file federal court claim damage base law state allege orthomcneil alza violate antitrust law state knowingly pursue baseless patent litigation delay entry market mylan impax action mylan involve orthomcneil levaquinr levofloxacin trial judge december find patent issue valid enforceable infringe mylan anda product issue injunction precluding sale product patent expiration late december court appeal federal circuit affirm judgment validity enforceability infringement mylan file motion rehear court appeal consolidated action teva sicor hitech pharmacal american pharmaceutical partner involve andas levofloxacin preparation trial tentatively schedule begin april claim levaquin patent obtain inequitable conduct unenforceable action kali involve orthomcneil ultracetr tramadol hydrochlorideacetaminophen kali move summary judgment issue infringement invalidity briefing motion complete october decision expect anytime respect claim issue litigation kali orthomcneil file reissue application patent trademark office seek narrow scope claim notice allowance patent receive october kali obtain final approval anda expiration month stay april launch generic product day orthomcneil ultimately prevail patent infringement action kali kali subject injunction damage action teva pharmaceuticals usa teva involvingorthomcneil ultracetr tramadol hydrocholorideacetaminophen teva move summary judgment issue infringement validity briefing motion complete march ruling issue point action caraco involve orthomcneil ultracetr tramadol hydrocholorideacetaminophen caraco motion summary judgment noninfringement grant october orthomcneil appeal decision caraco launch generic ultracetr risk december respect matter johnson johnson subsidiary involve vigorously defend validity enforceability assert infringement licensor patent average wholesale price awp litigation johnson johnson pharmaceutical subsidiary numerous pharmaceutical company defendant series lawsuit state federal court involve allegation pricing market certain pharmaceutical product amount fraudulent actionable conduct thing company allegedly report inflated average wholesale price awp drug issue case federal action state action remove federal court consolidated pretrial purpose multidistrict litigation mdl federal district court boston massachusetts plaintiffs case include class private person entity pay portion purchase drug issue base awp state government entity medicaid payment drug issue base awp mdl proceeding boston plaintiffs move class certification portion claim august trial judge certify massachusetts class private insurer provide medigap insurance coverage private payer physicianadministere drug payment base awp judge allow plaintiff file new complaint seek proper party represent national class individual copayment physicianadministere drug cover medicare court appeal decline allow appeal issue january hear class certification issue court indicate intent certify national class note new york state attorney general office federal trade commission issue subpoenas january february seek document relate marketing suture endoscopic instrument company ethicon ethicon endosurgery subsidiary february advise closed investigation connecticut state attorney general office issue subpoena document subpoena focus bundle suture endoscopic instrument contract offer group purchasing organization individual hospital discount predicate hospital achieving specify market share target category product operating company involve respond subpoenas june company receive request record information house representatives committee energy commerce connection investigation pharmaceutical reimbursement rebate medicaid committee request focus drug remicader infliximab market company centocor inc centocor subsidiary july centocor receive note consolidated financial statement request voluntarily provide document information criminal division attorney office district new jersey connection investigation centocor marketing practice subsequent request document receive attorney office company centocor respond process respond request document information august securities exchange commission sec advise company informal investigation foreign corrupt practice act allegation payment polish governmental official pharmaceutical company november sec advise company investigation formal issue subpoena information previously request informal fashion addition background document company operating unit poland respond request december orthomcneil receive subpoena united states attorney office boston massachusetts seek document relate marketing include alleged offlabel marketing drug topamaxr topiramate orthomcneil cooperating respond subpoena october attorney office boston ask attorney orthomcneil cooperate facilitating subpoena testimony present orthomcneil employee grand jury boston cooperation secure testimony additional witness grandjury request provide january janssen receive subpoena office inspector general united states office personnel management seek document concern sale marketing payment physician connection sale marketing clinical trial risperdalr risperidone document subsequent request additional subpoena seek information marketing adverse reaction risperdalr receive united states attorney office eastern district pennsylvania november janssen cooperating respond subpoenas april company pharmaceutical company request submit information senate finance committee use nominal pricing exception calculate good price medicaid rebate program request send manufacturer drug reimburse medicaid program company pharmaceutical company respond request february request supplemental information receive senate finance committee respond company pharmaceutical company july company receive letter request new york state attorney general office document pertain marketing offlabel sale clinical trial topamaxr topiramate risperdalr risperidone procritr epoetin alfa razadynetm galantamine hbr remicader infliximab aciphexr rabeprazole sodium company respond request august johnson johnson health care systems inc hcs johnson johnson subsidiary receive subpoena dallas texas attorney office seek document relate relationship group purchasing organization novation hcs johnson johnson subsidiaries company subsidiary involve respond subpoena september ortho biotech inc ortho biotech johnson johnson subsidiary receive subpoena office inspector general denver colorado field office seek document direct sale marketing procritr epoetin alfa present dealing oncology inc healthcare service network oncologist ortho biotech respond subpoena march depuy orthopaedics inc depuy johnson johnson subsidiary receive subpoena attorney office district new jersey seek record concern contractual relationship depuy surgeon surgeon training involve hip knee replacement reconstructive surgery lead orthopaedic company know receive subpoena depuy respond subpoena june united states senate committee finance request company produce information use educational grant similar request send major pharmaceutical company july committee specifically request information educational grant connection drug propulsidr follow request receive committee additional information january company process respond recent request july scios inc scios johnson johnson subsidiary receive subpoena united states attorney office district massachusetts seek document relate sale marketing natrecorr scio respond subpoena early august scio advise investigation handle united states attorney office northern district california san francisco september johnson johnson receive subpoena united states attorney office district massachusetts seek document relate sale marketing drug omnicare inc manager pharmaceutical benefit longterm care facilities johnson johnson subsidiaries involve process respond subpoena january janssen receive civil investigative demand texas attorney general seek broad category document relate sale marketing risperdalr janssen process respond request september plaintiff employment discrimination litigation initiate company federal district court new jersey move certify class african american hispanic salaried employee company affiliate employ time november present plaintiff seek monetary damage period present include punitive damage equitable relief company file response plaintiff class certification motion johnson johnson annual report company dispute allegation lawsuit vigorously defend company wholly own ethicon ethicon endosurgery subsidiary defendant federal antitrust action challenge suture endomechanical contract group purchasing organization andhospital discount predicate hospital achieving specify market share target category product case plaintiff seek substantial monetary damage injunctive relief action apply medical ethicon inc cdca file september conme johnson johnson sdny file november genico ethicon inc file october december purport class action file behalf purchaser endomechanical instrument action caption delaware valley surgical supply inc johnson johnson niagara fall memorial medical center johnson johnson file federal district court central district california remand federal circuit court appeal january partial retrial commence october conclude november federal district court boston massachusetts action amgen inc amgen transkaryotic therapy inc tkt aventis pharmaceutical inc aventis matter patent infringement action bring amgen tkt developer geneactivate epo product aventis hold marketing right tkt product assert tkt product infringe amgen patent claim tkt aventis dispute infringement seek invalidate amgen patent assert october district court issue ruling uphold initial finding amgen patent claim valid infringe appeal court appeal federal circuit argue december amgen patent issue case exclusively license ortho biotech nondialysis indication ortho biotech party action november amgen file suit hoffmannlaroche inc united states district court district massachusetts seek declaration roche product cera roche indicate seek introduce united states infringe number amgen patent concern epo suit preliminary stage company involve number patent trademark lawsuit incidental business ultimate legal financial liability company respect claim lawsuit proceeding refer estimate certainty company opinion base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company balance sheet expect material adverse effect company financial position resolution report period matter significant impact company result operation cash flow period earning share follow reconciliation basic net earning share dilute net earning share year end january january december table caption share millions basic net earning share average share outstandingbasic potential share exercisable stock option plan share repurchase treasury stock method convertible debt share adjust average share outstandingdilute diluted net earning share table dilute net earning share calculation include dilutive effect convertible debt decrease interest expense million million million tax year respectively diluted net earning share exclude million million million share underlie stock option respectively exercise price option great average market value result antidilutive effect dilute earning share capital treasury stock change treasury stock weretable caption treasury stock amount million treasury stock number share thousand share balance december employee compensation stock option plan conversion subordinate debenture repurchase common stock balance december employee compensation stock option plan conversion subordinate debenture repurchase common stock balance january employee compensation stock option plan conversion subordinate debenture repurchase common stock balance january table share common stock issue share end cash dividend pay share compare dividend share share note consolidated financial statement table caption select quarterly financial datum unaudite select unaudited quarterly financial datum year summarize second fourth second fourth dollar million share datum quarter quarter quarter quarter quarter quarter quarter quarter segment sale customer consumer pharmaceutical med device diagnostic total sale gross profit earning provision taxis income net earning basic net earning share dilute net earning share table second quarter include aftertax charge million inprocess research development iprd million tax benefit reversal tax liability relate technical correction associate american jobs creation act fourth quarter include aftertax charge million iprd shift sale low tax jurisdiction expenditure high tax jurisdiction significant impact fiscal fourth quarter tax rate quarter include aftertax charge million iprd fourth quarter include million taxis repatriation unremitted foreign earning associate american jobs creation act subsequent event january definitive agreement acquire guidant corporation guidant terminate guidant accordance term pursuant term agreement guidant pay company fee million january fiscal fourth quarter company announce acquisition animas corporation leading maker insulin infusion pump related product purchase price net cash acquire transaction approximately million close fiscal quarter fiscal quarter company complete acquisition hand innovation llc privately hold manufacturer widely fracture fixation product upper extremity management report internal control financial reporting section sarbanesoxley act management require assess effectiveness company internal control financial reporting end fiscal year report base assessment company internal control financial report effective management company responsible establish maintain adequate internal control financial reporting company internal control financial reporting design provide reasonable assurance reliability company financial reporting preparation financial statement accordance generally accept accounting principle internal control financial reporting matter design inherent limitation internal control financial reporting determine effective provide reasonable assurance respect financial statement preparation prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate company management assess effectiveness company internal control financial reporting january make assessment company criterion establish committee sponsor organization treadway commission coso internal controlintegrate framework criterion area control environment risk assessment control activity information communication monitor company assessment include extensive documenting evaluating testing design operating effectiveness internal control financial reporting base company process assessment describe management conclude january company internal control financial report effective management assessment effectiveness company internal control financial reporting january audit pricewaterhousecooper llp independent register public accounting firm state report appear johnson johnson annual report report independent register public accounting firm shareholder board directors johnson johnson complete integrate audits johnson johnson consolidated financial statement year end january january internal control financial reporting january audit consolidated financial statement year end december accordance standard public company accounting oversight board united states opinion base audit present consolidated financial statement opinion accompany consolidated balance sheet relate consolidated statement earning statement equity statement cash flow present fairly material respect financial position johnson johnson subsidiaries company january january result operation cash flow year period end january conformity accounting principle generally accept united states america financial statements responsibility company management responsibility express opinion financial statement base audit conduct audits statement accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit financial statement include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion internal control financial reporting opinion management assessment include accompany management report internal control financial reporting company maintain effective internal control financial reporting january base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission coso fairly state material respect base criterion furthermore opinion company maintain material respect effective internal control financial reporting january base criterion establish internal controlintegrate framework issue coso company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion management assessment effectiveness company internal control financial reporting base audit conduct audit internal control financial reporting accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit internal control financial reporting include obtain understand internal control financial reporting evaluate management assessment testing evaluate design operating effectiveness internal control perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle company internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate pricewaterhousecooper llp new york new york february report independent register public accounting firm table caption summary operation statistical data johnson johnson subsidiarie dollar million share figure sale customersus sale customersinternational total sale cost product sell sell marketing administrative expense research expense purchase inprocess research development interest income interest expense net portion capitalize income expense net earning provision taxis income provision taxis income net earning percent sale customer dilute net earning share common stock percent return average shareholder equity percent increase previous year sale customer dilute net earning share supplementary expense datum cost material service total employment cost depreciation amortization maintenance repair total tax expense supplementary balance sheet datum property plant equipment net addition property plant equipment total asset longterm debt operate cash flow common stock information dividend pay share shareholder equity share market price share yearend close average share outstanding million basic diluted employee thousand dollar million share figure sale customersus sale customersinternational total sale cost product sell sell marketing administrative expense research expense purchase inprocess research development interest income interest expense net portion capitalize income expense net earning provision taxis income provision taxis income net earning percent sale customer dilute net earning share common stock percent return average shareholder equity percent increase previous year sale customer dilute net earning share supplementary expense datum cost material service total employment cost depreciation amortization maintenance repair total tax expense supplementary balance sheet datum property plant equipment net addition property plant equipment total asset longterm debt operate cash flow common stock information dividend pay share shareholder equity share market price share yearend close average share outstanding million basic diluted employee thousand table net interest income include cost material service category include taxis income payroll property business taxis johnson johnson annual report text document document typeex sequence filenameyexvhtm descriptionex subsidiary text html head titleextitle head body bgcolorffffff pagebreak alignleft stylebreakbeforealwaysnbsphp alignright bfont sizeexhibit fontb aligncenter bfont sizesubsidiariesfontb alignleftnbspnbspnbspnbspnbsp font sizejohnson johnson new jersey corporation domestic international subsidiary show januarynbsp certain subsidiary international subsidiary name significant aggregate johnson johnson parent font center table width aligncenter cellspace cellpadde border widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd colspantd tdtd aligncenter nowrapbfont sizejurisdiction offontbtd colspan aligncenter nowrapbfont sizename subsidiaryfontbtd tdtd aligncenter nowrapbfont sizeorganizationfontbtd colspan aligncenter nowraphr size noshadetd tdtd aligncenter nowraphr size noshadetd valignbottom bgcoloreeeeee colspan alignleft valigntopdiv stylemarginleft textindent font sizeus subsidiary fontdiv tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeadvance sterilization product service incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizealza corporation fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizealza land management incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizebiosense webster incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizecalifornia fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizecentocor biologicsnbspllc fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizepennsylvania fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizecentocor incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizepennsylvania fonttdtr tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizecentocor researchnbspnbspdevelopment incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizepennsylvania fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeclosure medical corporation fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizecna development llc fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizecodman shurtleff incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizecordis corporation fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeflorida fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizecordis development corporation fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeflorida fonttd tdfont sizenbspfonttdtd alignleft valigntop div stylemarginleft textindent font sizecordis international corporation fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizecordis llc fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizecordis neurovascularnbspincnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeflorida fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizedepuy disc incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizedepuy incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizedepuy mitek incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizemassachusett fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizedepuy orthopaedic incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeindianafonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizedepuy product incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeindiana fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizedepuy spine incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeohio fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizedepuy spine sale limited partnership fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizemassachusett fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizediabete diagnostic incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeethicon endosurgery incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeohio fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeethicon endosurgery llcnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeethicon endosurgeryservicesnbsplpnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizetexas fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeethicon incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeethicon llc fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeglobal biologics supply chainnbspllc fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizepennsylvania fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizegynopharma incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeiso hold corpnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizejj holdings nevada incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenevada fonttd trtr tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizejanssen finance company fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeflorida fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizejanssen incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizejanssen ortho llc fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizejanssen lpnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizejjhcnbspllc fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson baby product incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd table center pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp center table width aligncenter cellspace cellpadde border widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd tdtd tdtd aligncenter nowrapbfont sizejurisdiction offontbtd aligncenter nowrapbfont sizename subsidiaryfontbtd tdtd aligncenter nowrapbfont sizeorganizationfontbtd aligncenter nowraphr size noshadetd tdtd aligncenter nowraphr size noshadetd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson consumer company incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson development corporation fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson finance corporation fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson health care system incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent pxfont sizejohnson johnson international fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson japan incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnsonnbspnbspmerck consumer pharmaceutical conbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson middle east incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson pharmaceutical research development llcnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson pharmaceutical services llc fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson pharmaceutical trading incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd trtd alignleft valigntop div stylemarginleft textindent font sizejohnsonnbsp johnson professional incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson sales logistics company llc fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson services incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson urban renewal associate fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson vision care incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeflorida fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejoint medical product corporation fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd alignleft valigntop div stylemarginleft textindent font sizelifescan incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizecalifornia fonttd trtr valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizelifescan llc fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd alignleft valigntop div stylemarginleft textindent font sizemcneil healthcare llcnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizemcneil nutritionalsnbspllc fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd alignleft valigntop div stylemarginleft textindent font sizemcneilppc incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizemiddlesex assurance company limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizevermont fonttd alignleft valigntop div stylemarginleft textindent font sizeneutrogena corporation fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizenitinol development corporation fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizecalifornia fonttdtr alignleft valigntop div stylemarginleft textindent font sizenoramco incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizegeorgia fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizeomj pharmaceutical incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd alignleft valigntop div stylemarginleft textindent font sizeorapharma incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizeortho biologics llc fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd alignleft valigntop div stylemarginleft textindent font sizeortho biotech clinical affairs llc fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizeortho biotech hold corpnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd alignleft valigntop div stylemarginleft textindent font sizeortho biotech incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd trtr valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizeortho biotech products lpnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd alignleft valigntop div stylemarginleft textindent font sizeorthoclinical diagnostic incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew york fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizeorthomcneil finance conbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeflorida fonttd alignleft valigntop div stylemarginleft textindent font sizeorthomcneil incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizeorthomcneil neurologic incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd alignleft valigntop div stylemarginleft textindent font sizeorthomcneil pharmaceutical incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizerutan realty llc fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd alignleft valigntop div stylemarginleft textindent pxfont sizescios incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizeterame corporation fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd alignleft valigntop div stylemarginleft textindent font sizetherapeutic discovery corporation fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizethe tylenol company fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenew jersey fonttd alignleft valigntop div stylemarginleft textindent font sizetransform pharmaceutical incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizewinthorpe valentine incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizedelaware fonttd table center pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp center table width aligncenter cellspace cellpadde border widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttdtr colspantd tdtd aligncenter nowrapbfont sizejurisdiction offontbtd colspan aligncenter nowrapbfont sizename subsidiaryfontbtd tdtd aligncenter nowrapbfont sizeorganizationfontbtd colspan aligncenter nowraphr size noshadetd tdtd aligncenter nowraphr size noshadetd valignbottom bgcoloreeeeee colspan alignleft valigntop div stylemarginleft textindent font sizeinternational subsidiary fontdiv tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizealza ireland limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeireland fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeapsis sasnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizefrance fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizecentocor biologics ireland limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeireland fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizecentocornbspbvnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenetherland fonttd trtdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizecilag advanced technologiesnbspgmbh fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeswitzerland fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizecilag fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeswitzerland fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizecilag mexico fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizemexico fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizecilag gmbh international fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeswitzerland fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizecilag holding fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeswitzerland fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizecodman sarl fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeswitzerland fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent pxfont sizecordis europa nvnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenetherland fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizecordis medizinische apparate gmbhnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizegermany fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizecordis sasnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizefrance fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizedepuy ace sarlnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeswitzerland fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizedepuy france sasnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizefrance fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizedepuy international limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeunited kingdom fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizedepuy international holdings limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeunited kingdom fonttd trtr valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizedepuy ireland limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeireland fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizedepuy mitek sarl fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeswitzerland fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizedepuy orthopadie gmbh fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizegermany fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizedepuy orthopedie sas fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizefrance fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizedepuy spine sarlnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeswitzerland fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizedepuy holdings limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeunited kingdom fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntopdiv stylemarginleft textindent font sizedrumbeat limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeireland fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeethicon gmbh fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizegermany fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeethicon ireland limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeireland fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeethicon sarl fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizescotland fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeethicon sas fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizefrance fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizeethnor proprietary limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizesouth africa fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizegreiter fontdivtd tdfont sizenbspfonttd alignleft valignbottom font sizeswitzerland fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizegreiter international fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeswitzerland fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizehigh wycombe property management limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeunited kingdom fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizejanssen animal health bvba fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizebelgium fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizejanssencilag fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenorway fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizejanssencilag fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizesweden fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizejanssencilag fontdiv tdfont sizenbspfonttd alignleft valignbottomfont sizeswitzerland fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizejanssencilag bvnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenetherland fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizejanssencilag farmaceutica ldanbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeportugal fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizejanssencilag farmaceutica ltdanbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizebrazil fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizejanssencilag gmbh fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizegermany fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizejanssencilag ltdnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeunited kingdom fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizejanssencilag nvnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizebelgium fonttd tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent pxfont sizejanssencilag pharmaceutical sacinbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizegreece fonttd valignbottom bgcoloreeeeee tdfont sizenbspfonttd alignleft valigntop div stylemarginleft textindent font sizejanssencilag pharma gmbh fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeaustria fonttd table center pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp center table width aligncenter cellspace cellpadde border widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd tdtd tdtd aligncenter nowrapbfont sizejurisdiction offontbtd aligncenter nowrapbfont sizename subsidiaryfontbtd tdtd aligncenter nowrapbfont sizeorganizationfontbtd aligncenter nowraphr size noshadetd tdtd aligncenter nowraphr size noshadetd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejanssencilag polskanbspspnbspznbspoo fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizepoland fonttd alignleft valigntop div stylemarginleft textindent font sizejanssencilag pty ltdnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeaustralia fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent pxfont sizejanssencilag sanbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizespain fonttd alignleft valigntop div stylemarginleft textindent font sizejanssencilag cvnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizemexico fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejanssencilag sasnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizefrance fonttd alignleft valigntop div stylemarginleft textindent font sizejanssencilag spanbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeitaly fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejanssen korea ltdnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizekorea fonttd alignleft valigntop div stylemarginleft textindent font sizejanssenortho incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizecanada fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejanssen pharmaceutica nvnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizebelgium fonttd alignleft valigntop div stylemarginleft textindent font sizejanssen pharmaceutica pty limited fontdiv tdfont sizenbspfonttdtd alignleft valignbottom font sizesouth africa fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejanssen pharmaceutical kknbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizejapan fonttd alignleft valigntop div stylemarginleft textindent font sizejanssen pharmaceutical limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeireland fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejcnbspgeneral servicesnbspcvba fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizebelgium fonttd alignleft valigntop div stylemarginleft textindent font sizejc healthcare ltdnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeisrael fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejhc nederland bvnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenetherland fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizesweden fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson fontdiv tdfont sizenbspfonttdtd alignleft valignbottom font sizeswitzerland fonttd alignleft valigntop div stylemarginleft textindent font sizejohnsonnbsp johnson china investmentnbspco ltdnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizechina fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson china ltdnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizechina fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson comercio distribuicao ltdanbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizebrazil fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson consumer france sasnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizefrance fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson consumer hongnbspkong limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizehong kong fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson argentina sace inbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeargentina fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson colombiasanbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizecolombia fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson venezuela sanbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizevenezuela fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson european treasury company fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeireland fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson egypt saenbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeegypt fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson finance limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeengland fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson gesellschaft mbh fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeaustria fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson gmbh fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizegermany fonttd valignbottom bgcoloreeeeee alignleft valigntopdiv stylemarginleft textindent font sizejohnson johnson group holdings gmbhnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizegermany fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson hellas sanbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizegreece fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson holding fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizesweden fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson hold gmbh fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizegermany fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson hong kong limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizehong kong fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizecanada fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson industrial ltdanbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizebrazil fonttd trtd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson international financial service company fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeireland fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson ireland limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeireland fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson kftnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizehungary fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson kknbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizejapan fonttd alignleft valigntop div stylemarginleft textindent font sizejohnsonnbsp johnson koreanbspltdnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizekorea fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson limitada fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeportugal fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeindia fonttd trtr valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson management limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeengland fonttd table center pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp center table width aligncenter cellspace cellpadde border widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd tdtd tdtd aligncenter nowrapbfont sizejurisdiction offontbtd aligncenter nowrapbfont sizename subsidiaryfontbtd tdtd aligncenter nowrapbfont sizeorganizationfontbtd aligncenter nowraphr size noshadetd tdtd aligncenter nowraphr size noshadetd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson medical bvnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizenetherland fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson medical china ltdnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizechina fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnsonnbspnbspjohnson medical holdingnbspspanbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeitaly fonttd trtr alignleft valigntop div stylemarginleft textindent font sizejohnson johnson medical korea limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizekorea fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson medical limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeunited kingdom fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson medical mexico cvnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizemexico fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnsonnbspnbspjohnson medical productsnbspgmbh fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeaustria fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson medical pty limitednbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizesouth africa fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson medical pty limitednbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeaustralia fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson medical sanbspfontdiv tdfont sizenbspfonttd alignleft valignbottomfont sizeargentina fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson medical shanghai ltdnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizechina fonttd alignleft valigntop div stylemarginleft textindent font sizejohnsonnbspnbspjohnson medicalnbspspanbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeitaly fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnsonnbspnbspjohnsonnbspnbspmerck consumer pharmaceutical canada fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizecanada fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson pacific pty limitednbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeaustralia fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson pakistan private limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizepakistan fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson philippines incnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizephilippine fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson poland zoonbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizepoland fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson produtos profissionais ltdanbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizebrazil fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson proprietary limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizesouth africa fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson pte ltdnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizesingapore fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson pty limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeaustralia fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson research pty ltdnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeaustralia fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson sanbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizespain fonttd alignleft valigntop div stylemarginleft textindent pxfont sizejohnson johnson cvnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizemexico fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson sdn bhdnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizemalaysia fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson spanbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeitaly fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnsonnbspsronbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeczech republic fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson swiss finance company limitednbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeunited kingdom fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson taiwan ltdnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizetaiwan fonttd alignleft valigntop div stylemarginleft textindent font sizejohnson johnson thailand ltd fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizethailand fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizejohnson johnson vision care ireland limitednbspfontdivtd tdfont sizenbspfonttd alignleft valignbottom font sizeireland fonttd alignleft valigntop div stylemarginleft textindent font sizelaboratoire polivenbspsncnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizefrance fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizelatam property holding fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeireland fonttd alignleft valigntop div stylemarginleft textindent font sizelifescan canada ltdnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizecanada fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizelifescan scotlandnbspltdnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizescotland fonttd alignleft valigntop div stylemarginleft textindent font sizemcneil gmbhnbspnbspconbspohg fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizegermany fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizemcneil ibericanbspslunbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizespain fonttd alignleft valigntop div stylemarginleft textindent font sizemcneilnbsppdinbspincnbspfontdiv tdfont sizenbspfonttdtd alignleft valignbottom font sizecanada fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizemcneilnbspsas fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizefrance fonttd alignleft valigntop div stylemarginleft textindent font sizemedo international sarl fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeswitzerland fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizemedo sarl fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeswitzerland fonttd alignleft valigntop div stylemarginleft textindent font sizeomj ireland limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeireland fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizeomj manufacture limited fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeireland fonttd alignleft valigntop div stylemarginleft textindent font sizeorthoclinical diagnostic fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeunited kingdom fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizeorthoclinical diagnostic gmbhfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizegermany fonttd table center pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp center table width aligncenter cellspace cellpadde border widthfont sizenbspfonttd widthfont sizenbspfonttd widthfont sizenbspfonttd tdtd tdtd aligncenter nowrapbfont sizejurisdiction offontbtd aligncenter nowrapbfont sizename subsidiaryfontbtd tdtd aligncenter nowrapbfont sizeorganizationfontbtd aligncenter nowraphr size noshadetd tdtd aligncenter nowraphr size noshadetd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizeorthoclinical diagnostic kknbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizejapan fonttd alignleft valigntop div stylemarginleft textindent font sizeorthoclinical diagnostic fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizebelgium fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizeorthoclinical diagnostic sasnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizefrance fonttd alignleft valigntop div stylemarginleft textindent font sizept johnson johnson indonesia fontdivtd tdfont sizenbspfonttd alignleft valignbottom font sizeindonesia fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizeshanghai johnson johnson pharmaceuticals ltd fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizechina fonttd alignleft valigntop div stylemarginleft textindent font sizetasmanian alkaloid pty ltdnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeaustralia fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizetibotec bvba fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizebelgium fonttd alignleft valigntop div stylemarginleft textindent font sizetibotec pharmaceutical ltdnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeireland fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent font sizetibotecvirco comm fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizebelgium fonttd alignleft valigntop div stylemarginleft textindent font sizeturnbuckle investment company fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizeireland fonttd valignbottom bgcoloreeeeee alignleft valigntop div stylemarginleft textindent pxfont sizevania expansion snc fontdiv tdfont sizenbspfonttd alignleft valignbottom font sizefrance fonttd alignleft valigntop div stylemarginleft textindent font sizexianjanssen pharmaceutical ltdnbspfontdiv tdfont sizenbspfonttd alignleft valignbottom font sizechina fonttd table center body html text document document typeex sequence filenameyexvhtm descriptionex consent independent register public accounting firm text html head titleextitle head body bgcolorffffff pagebreak alignleft stylebreakbeforealwaysnbsphp alignright bfont sizeexhibit fontb aligncenter bfont sizeconsent independent register public accounting firmfontb alignleftnbspnbspnbspnbspnbsp font sizewe consent incorporation reference registration statement form nonbsp formnbsp nonbsp johnson johnson report date februarynbsp relate financial statement management assessment effectiveness internal control financial reporting effectiveness internal control financial reporting appear annual report shareholder incorporate annual report formnbspk consent incorporation reference report date februarynbsp relate financial statement schedule appear formnbspk font alignleft font size pricewaterhousecooper llp font div alignleft size width alignleft colorblack noshade div div alignleft font sizepricewaterhousecooper llp font divp alignleft font sizenew york new york font div alignleft font sizemarchnbsp font div body html text document document typeexa sequence filenameyexvwahtm descriptionexa certification text html head titleexatitle head body bgcolorffffff pagebreak alignleft stylebreakbeforealwaysnbsphp alignright bfont sizeexhibit afontb aligncenter bfont sizecertification chief executive officerfontb div aligncenter bfont sizepursuant sectionnbsp sarbanesoxley actfontb div alignleftnbspnbspnbspnbspnbsp font sizei william weldon certify font table width border cellpadding cellspace widthtd widthtd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizenbspnbspnbspnbspnbspi review annual report formnbspk fiscal year end januarynbsp report johnson johnson company fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizenbspnbspnbspnbspnbspbase knowledge report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover report fonttd tdnbsptd trtr valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizenbspnbspnbspnbspnbspbase knowledge financial statement financial information include report fairly present material respect financial condition result operation cash flow company period present report fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizenbspnbspnbspnbspnbspthe company certify officer responsible establish maintain disclosure control procedure define exchange act rulenbspae internal control financial reporting define exchange act rule company fonttd table table width border cellpadding cellspace widthtd widthtd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizeanbspdesigne disclosure control procedure cause disclosure control procedure design supervision ensure material information relate company include consolidated subsidiary known entity particularly period report prepare fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizebnbspdesigne internal control financial reporting cause internal control financial reporting design supervision provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizecnbspevaluate effectiveness company disclosure control procedure present report conclusion effectiveness disclosure control procedure end period cover report base evaluation fonttdtr tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizednbspdisclose report change company internal control financial reporting occur company fourth fiscal quarter materially affect reasonably likely materially affect company internal control financial reporting fonttd table table width border cellpadding cellspace widthtd widthtd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizenbspnbspnbspnbspnbspthe company certify officer disclose base recent evaluation internal control financial reporting company auditor audit committee company board director person perform equivalent function fonttd table table width border cellpadding cellspace widthtd widthtd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizeanbspall significant deficiency material weakness design operation internal control financial reporting reasonably likely adversely affect company ability record process summarize report financial information fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizebnbspany fraud material involve management employee significant role company internal control financial reporting fonttd table table width border cellpadding cellspace trtd widthtd widthtd valigntop tdnbsptd alignleft font size william weldon fonttd valigntop tdnbsptd alignleft size alignleft colorblack noshadetd valigntop tdnbsptd aligncenter font sizewilliam weldon fonttd valigntop tdnbsptd aligncenter ifont sizechief executive officerfontitd table alignleft font sizedatenbspmarchnbsp font body html text document document typeexb sequence filenameyexvwbhtm descriptionexb certification text html head titleexbtitle head body bgcolorffffff pagebreak alignleft stylebreakbeforealwaysnbsphp alignright bfont sizeexhibit bfontb aligncenter bfont sizecertification chief financial officerfontb div aligncenter bfont sizepursuant sectionnbsp sarbanesoxley actfontb div alignleftnbspnbspnbspnbspnbsp font sizei robertnbspj darretta certify font table width border cellpadding cellspace widthtd widthtd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizenbspnbspnbspnbspnbspi reviewedthis annual report formnbspk fiscal year end januarynbsp report johnson johnson company fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizenbspnbspnbspnbspnbspbase knowledge report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover report fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizenbspnbspnbspnbspnbspbase knowledge financial statement financial information include report fairly present material respect financial condition result operation cash flow company period present report fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizenbspnbspnbspnbspnbspthe company certify officer responsible establish maintain disclosure control procedure define exchange act rulenbspae internal control financial reporting define exchange act rule company fonttd table table width border cellpadding cellspace widthtd widthtd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizeanbspdesigne disclosure control procedure cause disclosure control procedure design supervision ensure material information relate company include consolidated subsidiary known entity particularly period report prepare fonttd tdnbsptd trtr valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizebnbspdesigne internal control financial reporting cause internal control financial reporting design supervision provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizecnbspevaluate effectiveness company disclosure control procedure present report conclusion effectiveness disclosure control procedure end period cover report base evaluation fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizednbspdisclose report change company internal control financial reporting occur company fourth fiscal quarter materially affect reasonably likely materially affect company internal control financial reporting fonttd table table width border cellpadding cellspace widthtd widthtd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizenbspnbspnbspnbspnbspthe company certify officer disclose base recent evaluation internal control financial reporting company auditor audit committee company board director person perform equivalent function fonttd table table width border cellpadding cellspace widthtd widthtd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizeanbspall significant deficiency material weakness design operation internal control overfinancial reporting reasonably likely adversely affect company ability record process summarize report financial information fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizebnbspany fraud material involve management employee significant role company internal control financial reporting fonttd table table width border cellpadding cellspace widthtd widthtd valigntop tdnbsptd alignleft font size robert darretta fonttd valigntop tdnbsptd alignleft size alignleft colorblack noshadetd valigntop tdnbsptd aligncenter font sizerobert darretta fonttd valigntop tdnbsptd aligncenter ifont sizechief financial officerfontitd table alignleft font sizedatenbspmarchnbsp font body html text document document typeexa sequence filenameyexvwahtm descriptionexa certification text html head titleexatitle head body bgcolorffffff pagebreak alignleft stylebreakbeforealwaysnbsphp alignrightbfont sizeexhibit afontb aligncenter bfont sizecertification chief executive officerfontb div aligncenter bfont sizepursuant sectionnbsp sarbanesoxley actfontb div alignleftnbspnbspnbspnbspnbsp font sizethe undersigned william weldon chief executive officer johnson johnson new jersey corporation company pursuant nbspuscnbsp adopt pursuant sectionnbsp sarbanesoxley act certifie good knowledge font table width border cellpadding cellspace widthtd widthtd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizenbspthe company annual report formnbspk fiscal year end januarynbsp report fully complie requirement sectionnbspa securities exchange act fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizenbspthe information contain report fairly present material respect financial condition result operation company fonttd table table width border cellpadding cellspace widthtd widthtd valigntop tdnbsptd alignleft font size william weldon fonttd valigntop tdnbsptd alignleft size alignleft colorblack noshadetd valigntop tdnbsptd aligncenter font sizewilliam weldon fonttd trtr valigntop tdnbsptd aligncenter ifont sizechief executive officerfontitd table alignleft font sizedatednbspmarchnbsp font alignleftnbspnbspnbspnbspnbsp font sizethis certification furnish sec report formnbspk pursuant sectionnbsp sarbanesoxley act shall extent require act deem file company purpose sectionnbsp securities exchange act font body html text document document typeexb sequence filenameyexvwbhtm descriptionexb certification text html head titleexbtitle head body bgcolorffffff pagebreak alignleft stylebreakbeforealwaysnbsphp alignright bfont sizeexhibit bfontb aligncenter bfont sizecertification chief financial officerfontb div aligncenter bfont sizepursuant sectionnbsp sarbanesoxley actfontb div alignleftnbspnbspnbspnbspnbsp font sizethe undersigned robertnbspj darretta chief financial officer johnson johnson new jersey corporation company pursuant nbspuscnbsp adopt pursuant sectionnbsp sarbanesoxley act certifie good knowledge font table width border cellpadding cellspace widthtd widthtd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizenbspthe company annual report formnbspk fiscal year end januarynbsp report fully complie requirement sectionnbspa securities exchange act fonttd tdnbsptd trtr valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizenbspthe information contain report fairly present material respect financial condition result operation company fonttd table table width border cellpadding cellspace widthtd widthtd valigntop tdnbsptd alignleft font size robert darretta fonttd valigntop tdnbsptd alignleft size alignleft colorblack noshadetd valigntop tdnbsptd aligncenter font sizerobert darretta fonttd valigntop tdnbsptd aligncenter ifont sizechief financial officerfontitd table alignleft font sizedatednbspmarchnbsp font alignleftnbspnbspnbspnbspnbsp font sizethis certification furnish sec report formnbspk pursuant sectionnbsp sarbanesoxley act shall extent require act deem file company purpose sectionnbsp securities exchange act font body html text document document typeex sequence filenameyexvhtm descriptionex cautionary statement text html head titleextitle head body bgcolorffffff pagebreak alignleft stylebreakbeforealwaysnbsphp alignright bfont sizeexhibit fontbp aligncenter bfont sizecautionary statement pursuant private security litigation reformfontb div aligncenter bfont sizeact nbsp safe harbor forwardlooke statementsfontb div alignleftnbspnbspnbspnbspnbsp font sizethe company time time certain forwardlooking statement publiclyrelease material write oral forwardlooking statement relate strictly historical current fact anticipate result base management plan subject uncertainty forwardlooke statement identify use word like plan expect anticipate estimate word similar meaning conjunction thing discussion future operation financial performance company strategy growth product development regulatory approval market position expenditure font alignleftnbspnbspnbspnbspnbsp font sizeforwardlooking statement base current expectation future event company guarantee forwardlooke statement accurate company believe reasonable expectation assumption investor realize underlying assumption prove inaccurate unknown risk uncertainty materialize actual result vary materially company expectation projection investor caution place undue reliance forwardlooke statement furthermore company assume obligation update forwardlooke statement result new information future event development font alignleftnbspnbspnbspnbspnbsp font sizesome important factor cause company actual result differ company expectation forwardlooke statement follow font table width border cellpadding cellspace widthtd widthtd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizeeconomic factor include inflation fluctuation interest rate currency exchange rate potential effect fluctuation revenue expense result margin fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizecompetitive factor include technological advance achieve patent attain competitor new product introduce competitor fonttd tdnbsptd trtr valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizechallenge company patent competitor allegation company product infringe patent party potentially affect company competitive position ability sell product question require payment past damage future royalty particular generic drug firm file abbreviate new drug application seek market generic form company key pharmaceutical product prior expiration applicable patent cover product event company successful defending result lawsuit generic version product issue introduce result substantial market share revenue loss fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizefinancial distress bankruptcy experience significant customer supplier impair ability case purchase company product pay product previously purchase meet obligation company supply arrangement fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizethe impact political economic condition terrorist attack part world military action overseas instability financial market result terrorism military action fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizeinterruption computer communication system include computer virus impair company ability conduct business communicate internally customer fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizehealth care change country result pricing pressure include continued consolidation health care provider trend manage care health care cost containment shift government primary payer health care expense government law regulation relate sale promotion reimbursement pricing generally fonttd trtable pagebreak phr noshadep alignleft stylebreakbeforealwaysnbsphp table width border cellpadding cellspace widthtd widthtd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizegovernment law regulation affect foreign operation include relate security law compliance trade monetary fiscal policy taxis price control regulatory approval new product license patent right include particular propose amendments hatchwaxman act implementation medicare prescription drug improvement modernization act possible drug reimportation legislation fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizecompetition research involve development improvement new exist product process particularly significant result time time product process obsolescence development new improved product important company success area business fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizechallenge difficulty inherent product development include potential inability successfully continue technological innovation complete clinical trial obtain regulatory approval united states abroad gain maintain market approval product possibility encounter infringement claim competitor respect patent intellectual property right preclude delay commercialization product fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizesignificant litigation adverse company include product liability claim patent infringement claim antitrust claim fonttd tdnbsptd valigntop tdnbsptdtd alignleftnbspnbspnbspnbspnbsp font sizethe health care industry come increase scrutiny government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty include debarment government business fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizeproduct efficacy safety concern base scientific evidence result product withdrawal recall regulatory action fda foreign counterpart decline sale fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizethe impact business combination include acquisition divestiture internally company externally pharmaceutical medical device health care industry fonttd tdnbsptd valigntop tdnbsptd alignleftnbspnbspnbspnbspnbsp font sizeissuance new revise accounting standard american institute certify public accountant financial accounting standard board securities exchange commission public company accounting oversight board fonttd table alignleftnbspnbspnbspnbspnbsp font sizethe foregoing list set forth factor impact company ability achieve result describe forwardlooke statement investor understand possible predict identify factor consider list complete statement potential risk uncertainty company identify factor list permit private security litigation reform act font body html text document secdocument end privacyenhance message